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Significant comorbidities between obesity-relatedmetabolic disease and stress-related psychological disor-
ders suggest important functional interactions between energy balance and brain stress integration. Largely
overlapping neural circuits control these systems, and this anatomical arrangement optimizes opportunities
for mutual influence. Here we first review the current literature identifying effects of metabolic neuroendo-
crine signals on stress regulation, and vice versa. Next, the contributions of reward-driven food intake to
these metabolic and stress interactions are discussed. Lastly, we consider the interrelationships between
metabolism, stress, and reward in light of their important implications in the development of therapies for
metabolism- or stress-related disease.Introduction
Obesity and associated metabolic diseases have long been
thought to exhibit significant comorbidity with stress-associated
psychological disorders like anxiety and depression (reviewed
by Anderson et al., 2001; Faith et al., 2002; Gariepy et al.,
2010; Hryhorczuk et al., 2013; Stunkard et al., 2003). For
example, two recent studies report that overweight or obesity
during the baseline period increased the risk of developing
depression during follow-up. On the other hand, baseline
depression significantly increased the odds for developing
obesity over time (Luppino et al., 2010; Pan et al., 2012). Such as-
sociations likely arise, at least in part, because neural circuits
governing energy balance and stress reactivity are substantially
intertwined, providing stress regulatory systems priority to redis-
tribute fuels in response to acute threats (or perceived threats) to
an individual’s well-being. The result is a reciprocal interaction
between stress and metabolism that has critical implications
for understanding the etiology of both metabolic disease and
stress-related psychological disorders and for developing thera-
peutic interventions.
Homeostatic Circuits
Energy Balance
The amount of body fat an individual maintains reflects a tightly
regulated homeostatic system matching energy intake with
energy expenditure. The central nervous system (CNS) plays a
key role to balance this energy equation. That is, the brain inte-
grates signals from the environment and the periphery regarding
energy needs and availability and recruits appropriate effector
systems to adjust behavioral and physiological responses that
act to maintain the system in balance. Considerable progress
has been made to elucidate the molecular and cellular pro-
cesses, primarily in the hypothalamus and brainstem, com-
prising these circuits. This homeostatic regulation integrates
acute satiation signals, arising in the gut and secreted phasically910 Cell Metabolism 19, June 3, 2014 ª2014 Elsevier Inc.during meals, with more tonically active adiposity signals to
appropriately adjust nutrient intake and energy expenditure
(Figure 1) (reviewed by Ryan et al., 2012; Schwartz et al., 2000;
Woods and D’Alessio, 2008).
Satiation signals provide information about acutely ingested
food and regulate meal size by acting locally at receptors on
vagal afferent nerves or by directly stimulating receptors in the
brainstem. Several satiation signals have been identified, includ-
ing glucagon-like peptide-1 (GLP-1), cholecystokinin (CCK),
peptide tyrosine-tyrosine (PYY), and amylin. These and other
postprandial signals converge in key brainstem regions including
the nucleus of the solitary tract (NTS) and area postrema (AP)
(reviewed by Adan et al., 2008; Moran, 2006; Woods and D’Ales-
sio, 2008). The NTS represents a critical node of convergence
that integrates meal-related signals from the periphery and also
relays this information to the hypothalamus; neurons in the NTS
project widely into the arcuate nucleus (ARC) and other hypo-
thalamic nuclei implicated in the control of energy homeostasis
(Grill, 2006; Grill and Hayes, 2012; Norgren, 1978). The end result
of activating this system is termination of a meal.
Whereas satiation signals provide information about acutely
ingested nutrients, the adiposity signals leptin and insulin pro-
vide information about stored fuel. Leptin is secreted from white
adipose tissue (WAT), and insulin is secreted from pancreatic
b cells, in proportion to total adiposity—providing accurate
information about the amount of body fat an individual maintains.
These hormones cross the blood brain barrier to signal directly at
their receptors in the ARC, ventromedial hypothalamic nucleus
(VMN), NTS, and elsewhere. When an individual acutely gains
weight, increased leptin and/or insulin signaling in the brain leads
to reduced food intake and increased energy expenditure,
thereby restoring body fat to defended levels (reviewed by Grill
and Hayes, 2012; Schwartz et al., 2000).
Both leptin and insulin exert their effects on energy balance
in part by activating the hypothalamic melanocortin system
Figure 1. Canonical Pathways that Regulate Stress Responses and
Energy Balance
For the stress system, information from brainstem and limbic forebrain areas
converges in the PVN, which directly activates the HPA axis and regulates
autonomic nervous system responses via projections to brainstem. For energy
balance, information from brainstem and limbic forebrain areas converge on
the ARC, which regulates energy intake and expenditure via connections to the
PVN, LHA, and brainstem.
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order pro-opiomelanocortin (POMC)- and agouti-related peptide
(AgRP)-expressing neurons in the ARC that project to melano-
cortin-4 receptor (MC4R)-positive neurons in the paraventricular
nucleus of the hypothalamus (PVN), the lateral hypothalamic
area (LHA), and elsewhere (reviewed by Cone, 2005). The pro-
hormone POMC is cleaved to produce a-MSH, an agonist of
MC4R, whereas AgRP acts as an inverse agonist at the receptor
(Haskell-Luevano and Monck, 2001; Haskell-Luevano et al.,
1997; Nijenhuis et al., 2001). Brain leptin and insulin signaling
activate POMC and inhibit AgRP neurons (Cowley et al., 2001;
van den Top et al., 2004). The net effect is to increase MC4R
signaling, and thereby to reduce food intake and increase energy
expenditure.
Importantly, signaling by adiposity signals sets a background
tone that modulates sensitivity to satiation signals. Meal-related
signals relayed from the brainstem are integrated in leptin- and/
or insulin-receptor-expressing neurons in the NTS and medial-
basal hypothalamus (MBH). These in turn recruit appropriate
downstream effectors (e.g., MC4R) in the PVN, LHA, parabra-
chial nucleus (PBN), NTS, dorsal motor nucleus of the vagus
(DMV), and intermediolateral cell column of the spinal cord
(IML) to appropriately modulate feeding behavior and energy
expenditure (reviewed by Williams and Elmquist, 2012). In the
presence of greater CNS leptin and/or insulin signaling, for
example, the anorectic responses to CCK (Morton et al., 2005;
Riedy et al., 1995) and GLP-1 (Williams et al., 2006) are
enhanced.
Stress
Stress is broadly defined as a real or perceived threat to homeo-
stasis or well-being and may be either physical or psychogenic
in nature. Information regarding the presence of a stressor is
conveyed by all major sensory systems to the brain, with threats
to physiological homeostasis conveyed primarily via brainstem
regions like the NTS, while psychogenic stressors impinge
primarily on forebrain limbic structures like the prefrontal cortex
(PFC), hippocampus, and amygdala (reviewed by Ulrich-Lai andHerman, 2009). The PVN represents an important node of
convergence that receives inputs from stress-activated brain-
stem and forebrain limbic structures. These signals are inte-
grated in the PVN to recruit appropriate effector systems that
adjust physiological responses—thereby minimizing the ex-
pected cost to the individual. Considerable progress has been
made to elucidate the neural circuits and cellular processes,
primarily in the limbic forebrain, hypothalamus, and brainstem,
which mediate these responses. These involve activation of
both the sympathoadrenomedullary (SAM) system and the
hypothalamic-pituitary-adrenocortical (HPA) axis (Figure 1).
Activation of the sympathetic nervous system during acute
stress provides a means for rapid physiological responses via
direct neural innervation of peripheral organs (reviewed by
Ulrich-Lai and Herman, 2009). Stress activates a collection of
preautonomic brain regions, including the NTS and PVN, that
ultimately activate presympathetic neurons in the IML and inac-
tivate preparasympathetic neurons in the DMV and nucleus
ambiguous. The IML neurons activate (1) postganglionic neurons
in the prevertebral and paravertebral ganglia, which provide
catecholaminergic innervation to nearly all peripheral tissues,
and (2) the adrenal medulla, which releases catecholamines
into systemic circulation. This SAM activity is responsible for
the stereotypical ‘‘fight or flight’’ response that includes
increased heart rate and blood pressure, redirection of blood
flow away from digestive and reproductive processes, and
mobilization of stored energy. For example, increased sym-
pathetic drive to WAT increases the release of free fatty acids
(reviewed by Bartness and Song, 2007). Similarly, increased
sympathetic drive to the liver in response to stress promotes
glycogenolysis and increases glucose output (reviewed by
Yamaguchi, 1992), whereas increased sympathetic drive to
pancreas blunts insulin secretion—contributing to the greater
availability of circulating glucose (reviewed in Halter et al., 1984).
Activation of the HPA axis provides a slower, sustained,
and amplified physiological response to acute stress (reviewed
in Ulrich-Lai and Herman, 2009). Specifically, information
regarding a stressor is conveyed to hypophysiotropic neurons
in the PVN. These neurons then release corticotropin-releasing
hormone (CRH), as well as other releasing factors, from their
terminals in the median eminence. The CRH is carried through
the portal circulation to the anterior pituitary, where it stimulates
the release of adrenocorticotropic hormone (ACTH) into sys-
temic circulation. ACTH stimulates the synthesis and secretion
of glucocorticoids (e.g., cortisol in humans and corticosterone
in rodents) from the adrenal cortex. Glucocorticoids act on
their receptors throughout the brain and body to exert numerous
effects, including negative feedback on CRH and ACTH release
and mobilization of stored energy. Specifically, glucocorticoids
mobilize fuel from the liver via increased gluconeogenesis
(reviewed in Baxter, 1976) and from WAT by increased lipolysis
(Campbell et al., 2011; Xu et al., 2009). The net effect is to
increase the availability of fuel, facilitating a physiological
response to the (real or perceived) threat. Taken together, rapid
SAM action coupled with the somewhat slower and longer-
lasting glucocorticoid actions work together to maintain phy-
siological homeostasis and promote survival.
Frequent use of stress regulatory circuits under conditions of
chronic stress exposure results in altered gene expression andCell Metabolism 19, June 3, 2014 ª2014 Elsevier Inc. 911
Table 1. Stress-Regulatory Effects of Metabolic Neuroendocrine Signals
Neuroendocrine Signal Energy Balance SAM System HPA Axis
CCK Y Gibbs and Smith, 1977;
Kraly et al., 1978
[ de Montigny, 1989;
Zwanzger et al., 2012
[ Maniscalco and Rinaman, 2013;
Kamilaris et al., 1992
Glp-1 Y Flint et al., 1998;
Turton et al., 1996
[ Griffioen et al., 2011;
Yamamoto et al., 2002
[ Kinzig et al., 2003; Larsen et al., 1997;
Ghosal et al., 2013; Tauchi et al., 2008
Ghrelin [ Tscho¨p et al., 2000;
Wren and Bloom, 2007
Y Lin et al., 2004;
Matsumura et al., 2002;
Huda et al., 2010;
Shimizu et al., 2011
[ Cabral et al., 2012; Spencer et al., 2012
Leptin Y Reviewed in Grill and
Hayes, 2012 and
Schwartz et al., 2000
[ Ren, 2004; da Silva et al.,
2006; Mark et al., 1999;
Pacak et al., 1995
[ Basal: van Dijk et al., 1997
Y Poststress: Pacak et al., 1995;
Heiman et al., 1997; Wilson et al., 2005
Insulin Y Reviewed in Grill and
Hayes, 2012 and
Schwartz et al., 2000
[ Muntzel et al., 1994;
Rowe et al., 1981;
Rahmouni et al., 2003
Y Bohringer et al., 2008
MC4R signaling Y Cowley et al., 2001;
van den Top et al., 2004;
Benoit et al., 2002;
Seeley et al., 1997
[ Rahmouni et al., 2003;
Tallam et al., 2006;
do Carmo et al., 2011;
Greenfield et al., 2009;
Sohn et al., 2013
[ Dhillo et al., 2002; Lu et al., 2003;
Liu et al., 2013; Ryan et al., 2014
Considerable research has established that metabolism-related neuroendocrine signals influence basal and stress-evoked activity of the SAM and
HPA systems. Upward arrows denote activation, whereas downward arrows denote inhibition.
Cell Metabolism
Perspectivesynaptic plasticity, leading to persistent changes in stress sys-
tem function (Ulrich-Lai and Herman, 2009). For instance,
chronic stress leads to dendritic atrophy in stress-inhibitory brain
regions (hippocampus, mPFC) (Magarin˜os and McEwen, 1995;
Radley et al., 2008), dendritic branching in stress-excitatory
brain regions (amygdala) (Vyas et al., 2002), and increased
neuronal inputs as well as increased CRH mRNA in the PVN
(Flak et al., 2009; Herman et al., 1995; Makino et al., 1995). The
net effect of these various changes to stress regulatory circuits
is increased excitability, leading to elevated basal and stress-
evoked HPA and SAM tone (Akana et al., 1992; Grippo et al.,
2002; Ulrich-Lai et al., 2007). This stress facilitation insures that
the system can respond to new stressors despite elevations
in basal glucocorticoids and alterations in endocrine and im-
mune function (Akana et al., 1992; Tauchi et al., 2008). In rodent
models, exposure to chronic stress often elicits an increase in
anxiety-like and depression-like behaviors. Therefore, varying
chronic stress paradigms have been developed to model these
disorders. Consistent with this association, a history of stressful
life events and/or circumstances is thought to be a significant
risk factor for clinical diagnosis of depression and other mood
disorders (Coyne and Downey, 1991; de Kloet et al., 2005;
Mazure, 1998; Paykel et al., 1969).
Integration of Energy Homeostasis and Stress
Regulatory Responses
An emergent property of these overlapping circuits is that acute
stress responses, initiated to maintain homeostasis across all
major physiological systems and/or to respond to environmental
threats, can commandeer metabolic circuits and endocrine re-
sponses to address acute threats to an individual’s well-being,
as discussed above. Energy and glucose homeostasis are
temporarily disrupted to provide fuel for these responses. More-
over, persistent exposure to circulating glucocorticoids during912 Cell Metabolism 19, June 3, 2014 ª2014 Elsevier Inc.chronic stress promotes the redistribution of body fat toward
visceral depots (Dallman et al., 2003; Lo¨nn et al., 1994), which
are thought to exhibit greater lipolytic response to adrenergic
stimulation (Arner, 1995; Hoffstedt et al., 1997; Ostman et al.,
1979). Thus, fat redistribution associated with chronic stress
may mirror stress facilitation in neural circuits by insuring the
system can rapidly mobilize fatty acids in response to new
stressors.
Importantly, growing evidence now suggests that information
regarding energy status conveyed by gut hormones, adiposity
signals, and other neurotransmitters involved in the regulation
of energy balance likewise may impinge on stress regulatory
systems, to directly activate or to modulate the intensity of
these responses during acute and chronic stress. These findings
are discussed below (and see Table 1).
Gut Hormones and Stress Reactivity
CCK. Cholysystokinin (CCK) is a peptide hormone secreted by
intestinal I cells in response to ingestion of nutrients, particularly
fat or protein. Systemic administration of CCK induces satiation,
evidenced primarily by a reduction in meal size (Gibbs and
Smith, 1977; Kraly et al., 1978). This can be attenuated by vagot-
omy or by the deactivation of vagal afferents with capsaicin
(Kraly et al., 1978; Raybould, 1991). CCK activates vagal afferent
fibers projecting to neurons in the NTS. Importantly, these
further project directly to the PVN, and ultimately contribute to
its activation of the HPA axis (Maniscalco and Rinaman, 2013).
Systemic administration of CCK increases plasma ACTH and
corticosterone, and these responses are attenuated by deacti-
vation of vagal afferents in capsaicin-treated animals (Kamilaris
et al., 1992). While these findings support the contention that
exogenous CCK is capable of activating the HPA axis via vagal
afferent stimulation, it is not yet clear if this reflects a physio-
logical role for postprandial gut-derived CCK to regulate stress
responses.
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distributed neuropeptide. Neurally derived CCK is implicated in
a range of physiological processes, including thermoregulation,
nociception, and cognition (Beinfeld, 2001). Increased central
CCK has been observed following stressful social interactions
in rats (Andre et al., 2005; Becker et al., 2008), suggesting both
gut- and brain-derived CCK may impinge on stress regulation.
Brain CCK is implicated in the regulation of emotional and moti-
vational states and is generally associated with increased SAM
activation. For example, exogenous administration of CCK can
trigger panic attacks in patients with panic disorder and in a
subset of the normal population, and this is associated with a
dose-dependent activation of the SAM response (de Montigny,
1989; Zwanzger et al., 2012).
GLP-1. GLP-1 is a peptide hormone secreted from enteroen-
docrine L cells into hepatic portal circulation in response to
ingestion of nutrients (Kreymann et al., 1987). It acts at its recep-
tor (GLP-1R) to augment insulin secretion from pancreatic b
cells, facilitating normal glucose tolerance (Baggio and Drucker,
2007; Holst, 2007), and it promotes satiety in both rodents and
humans (Flint et al., 1998; Turton et al., 1996). Consistent with
its anorectic effects, intracerebroventricular (icv) administration
of GLP-1 activates CRH-expressing neurons in the PVN. As
might be expected, this not only reduces food intake but also
results in activation of the HPA axis. Specifically, both icv and
intra-PVN infusion of GLP-1 increases plasma ACTH and corti-
costerone (Kinzig et al., 2003; Larsen et al., 1997), and these
hormonal responses can be abrogated by intra-PVN infusion of
a GLP-1R antagonist (Kinzig et al., 2003). Chronic GLP-1 admin-
istration alone does not alter basal HPA tone. However, chronic
activation of GLP-1R signaling contributes to chronic stress-
induced facilitation of corticosterone responses to a novel
stressor (Ghosal et al., 2013; Tauchi et al., 2008). Both peripheral
and central administrations of GLP-1 also increase sympathetic
tone. Specifically, peripheral administration of long-lasting GLP-
1R agonists activates neurons in the AP that project to the NTS,
PVN, PBN, and rostral ventrolateral medulla (RVLM) (Yamamoto
et al., 2002, 2003). In accordance with this, peripheral and cen-
tral administrations of GLP-1 agonists increase heart rate and
blood pressure in a dose-dependent manner (Griffioen et al.,
2011; Yamamoto et al., 2002).
GLP-1 is also produced in neurons in the brain, including in the
NTS. Notably, GLP-1 immunoreactive fibers originating in the
NTS project to important stress-regulatory regions, including
CRH-containing neurons in the PVN (Sarkar et al., 2003). This
brain GLP-1 system clearly plays a role in regulating stress
reactivity (reviewed by Ghosal et al., 2013), but the relative
physiological importance of gut-derived GLP-1 in stress regula-
tion remains to be determined. GLP-1R is expressed on vagal
afferent nerves, including those located in the nodose ganglia
(Nakabayashi et al., 1996; Vahl et al., 2007) and may thereby
impinge on stress circuitry via vagal afferent stimulation of the
brainstem, but this remains untested.
Ghrelin. Ghrelin is a peptide hormone secreted by specialized
cells in the stomach and duodenum and is the only gut hormone
known to act in the brain to increase food intake and body
weight (Tscho¨p et al., 2000; Wren and Bloom, 2007). It circulates
in an acylated and des-acylated form, with acylation thought
to be necessary for full agonism at its receptor, the growthhormone secretagogue receptor (GHSR) (Kojima et al., 1999).
Ghrelin acutely activates AgRP neurons and inhibits POMC
neurons in the ARC, contributing to its effects on feeding
behavior (Andrews et al., 2008; Cowley et al., 2003).
Intriguingly, circulating ghrelin and/or its mRNA is increased
following stress in both rodents and humans (Asakawa et al.,
2001; Lutter et al., 2008; Rouach et al., 2007), suggesting ghrelin
may play a physiological role to regulate stress responses.
Exogenous administration of ghrelin inhibits sympathetic tone
in rodents (Lin et al., 2004) and rabbits (Matsumura et al.,
2002) and in control, but not in vagotomized, human subjects
(Huda et al., 2010). Local administration of ghrelin directly into
the NTS decreases blood pressure and renal sympathetic nerve
activity by suppressing sympathetic drive (Lin et al., 2004), while
its icv administration activates the cardiac vagal nerve (Shimizu
et al., 2011).
Ghrelin signaling also impinges on HPA axis function. Specif-
ically, exogenous ghrelin administration increases activation of
CRH-producing neurons in the PVN and enhances both CRH
gene expression and circulating corticosterone (Cabral et al.,
2012). Ghrelin has likewise been reported to increase anxiety-
and depressive-like behavior (Asakawa et al., 2001; Carlini
et al., 2002, 2004; Kanehisa et al., 2006). On the other hand,
however, ghrelin-deficient mice also express more anxiety-like
behavior in the open field, and their stress-induced neuronal
activation in the PVN is increased relative to wild-type controls.
This can be rescued with exogenous ghrelin (Spencer et al.,
2012). These discrepancies have been difficult to reconcile, but
they are thought to result from different experimental conditions
as well as the type and duration of stressor used (reviewed by
Chuang and Zigman, 2010; Stengel et al., 2011). Importantly,
and consistent with the effect of exogenous ghrelin to increase
circulating glucocorticoids, the corticosterone response to
acute stress was substantially decreased in ghrelin knockout
mice—but this was attributed to direct action of ghrelin to
stimulate ACTH release from the anterior pituitary (Spencer
et al., 2012). Therefore, while it seems clear that ghrelin acts to
increase HPA axis output (i.e., circulating glucocorticoids),
further investigation is required to better delineate the underlying
mechanisms and neural substrates (see Schellekens et al. [2012]
for a more thorough review). In addition, growing evidence
suggests ghrelin action in brain reward circuitry can modulate
motivational aspects of food intake, impinging on the critical
interaction between food reward and physiological responses
to acute and chronic stress. This is further discussed below.
Adiposity Signals and Stress Reactivity
Leptin. As discussed above, leptin acts at its receptor (Lepr)
in the hypothalamus and brainstem to reduce food intake and
increase energy expenditure. Consistent with this, acute leptin
infusion activates the SAM system. Leptin increases sympa-
thetic nerve activity to multiple organs, including brown adipose
tissue, the adrenal gland, and the kidney, and its chronic infusion
increases heart rate, arterial blood pressure, and circulating cat-
echolamines (Ren, 2004; da Silva et al., 2006). Thus, increased
circulating leptin is thought to play a key role in obesity-associ-
ated hypertension (reviewed by Hall et al., 2010; Rahmouni,
2010). Conversely, leptin-deficient (ob/ob) mice fail to exhibit
hypertension, despite massive obesity, and Zucker rats, lacking
the Lepr, exhibit decreased basal and stress-induced plasmaCell Metabolism 19, June 3, 2014 ª2014 Elsevier Inc. 913
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induced sympathetic tone (Mark et al., 1999; Pacak et al., 1995).
Lepr-positive, leptin-responsive AgRP and POMC neurons in
the ARC project to and activate CRH-containing neurons in the
PVN, and at least some of leptin’s anorectic effects aremediated
by increased expression of CRH (Lu et al., 2003). In agreement
with this, it has been reported that leptin activates the HPA
axis in unstressed rats (van Dijk et al., 1997). However, in
contrast to its effects on the SAM system, leptin blunts HPA
axis responses to stress. Peripheral administration of leptin
reduces both ACTH and glucocorticoid responses to an acute
psychogenic stressor in mice (Heiman et al., 1997) and in rhesus
monkeys. In addition, leptin enhances glucocorticoid negative
feedback and blunts CRH-induced increases in both cortisol
and ACTH in monkeys (Wilson et al., 2005). Zucker rats and
ob/ob mice exhibit exaggerated corticosterone responses to
stress (Pacak et al., 1995). Furthermore, evidence supports a
role for leptin to blunt chronic stress-induced, depression-like
behavior and neural plasticity. Exogenous leptin administration
to rats undergoing chronic unpredictable stress abrogates
stress-induced increases in immobility during the forced swim
test and attenuates stress-induced suppression of hippocampal
neurogenesis (Garza et al., 2012).
Insulin. In addition to its critical role in the regulation of glucose
homeostasis, insulin acts at its receptors in the brain to reduce
food intake and increase energy expenditure. Consistent with
increased energy expenditure, both peripheral and icv adminis-
tration of insulin increase basal sympathetic nerve activity
(Muntzel et al., 1994; Rowe et al., 1981). Brain insulin action
also facilitates the sympathetic counterregulatory response to
hypoglycemia (Diggs-Andrews et al., 2010; Fisher et al., 2005),
but its ability to facilitate SAM activation in response to other
stressors remains uncertain. For example, while intranasal
insulin modulates the HPA response to the Trier Social Stress
Test (TSST) in human subjects (discussed below), it did not alter
the cardiovascular/autonomic response to this potent psycho-
logical stressor (Bohringer et al., 2008).
Both increased HPA axis activity and hyperinsulinemia are
frequently observed in patients with diabetes. However, the
effect of insulin per se on basal and stress-induced HPA tone
is less clear. Brain insulin signaling is thought to play a role to
stimulate the HPA axis during hypoglycemia counterregulation
(Davis et al., 1995; Fruehwald-Schultes et al., 1999), yet this
may not occur basally or during other types of stress. For
example, in apparent contrast to these findings, both lean and
obese individuals receiving chronic intranasal insulin, which first
reaches the cerebral spinal fluid without being absorbed into
the blood stream, exhibit significantly blunted morning HPA
axis activity (Bohringer et al., 2008). In addition, a single intra-
nasal insulin administration prior to a TSST significantly blunted
the stress-evoked rise in cortisol (Bohringer et al., 2008).
MC4R. MC4R is a well-described downstream effector of lep-
tin and insulin action on energy balance, and there is a growing
appreciation that it also plays an important role in brain stress
integration. ARC POMC neurons projecting to both the PVN
and medial amygdala (MeA) are rapidly activated by both acute
restraint and forced swim stress. Moreover, pharmacological
activation of MC4R in the PVN increases CRH mRNA as well
as circulating ACTH and corticosterone (Dhillo et al., 2002; Lu914 Cell Metabolism 19, June 3, 2014 ª2014 Elsevier Inc.et al., 2003). Pharmacologic activation of MC4R in the MeA
also acutely increases circulating corticosterone, whereas its
inhibition abrogates the rise in corticosterone elicited by acute
restraint stress (Liu et al., 2013). Consistent with this, stress-
induced activation of the HPA axis is attenuated in a rat model
ofMc4r loss of function (Ryan et al., 2014). In addition, evidence
supports a role for MC4R to facilitate an increase in anxiety-like
and depression-like behavior pursuant to chronic stress. Rela-
tive to control mice, MC4R-deficient mice spent significantly
more time exploring the open arm of the elevated plus maze,
less time immobile in the forced swim test, and more time
interacting with a social target following chronic social defeat
stress (CSDS) (Chuang et al., 2010).
With regard to the SAM system, it is thought that MC4R is a
key downstream effector of leptin and/or insulin action on sym-
pathetic drive (1) since the effect of exogenous leptin and insulin
to increase renal sympathetic nerve activity (Rahmouni et al.,
2003) and of exogenous leptin to increase blood pressure (Tal-
lam et al., 2006) was abolished in MC4R-deficient mice and (2)
since deleting Lepr specifically in POMC neurons abolishes the
rise in blood pressure associated with chronic leptin infusions
(do Carmo et al., 2011). In agreement with this, humans with a
loss-of-function mutation in MC4R have normal blood pressure
despite extreme obesity (Greenfield et al., 2009). The effects of
MC4R signaling on the SAM system likely involves direct action
in the brainstem and spinal cord, since ex vivo application of
MC4R agonists inhibit parasympathetic preganglionic neurons
in the DMV and activate sympathetic preganglionic neurons in
the IML of mice (Sohn et al., 2013). Although these findings sup-
port a role for MC4R to regulate basal (unstressed) sympathetic
drive, it is not yet known whether MC4R plays a role in SAM acti-
vation following acute or chronic stress.
It is interesting to note that, with regard to HPA axis regulation,
the effects of leptin and MC4R are dissociated. That is, while it is
well-known that leptin stimulates MC4R, contributing to its
downstream effects on energy balance, leptin, and MC4R
signaling seem to have opposing effects on HPA axis regulation.
Leptin blunts, whereas MC4R signaling facilitates, the HPA
response to stress. This may reflect that MC4R-ergic tone
integrates both short- and long-term regulators of energy bal-
ance. MC4R is not only a downstream effector of leptin and
insulin action but also contributes to the effects of various other
anorectic and orexigenic signals (reviewed by Ellacott and Cone,
2004). Likewise, CNS leptin action has both MC4R-dependent
and MC4R-independent effects.
Brain Reward Circuits
Reward and Energy Balance
Despite a robust homeostatic system governing energy balance,
evidence suggests the initiation of ameal, particularly in humans,
is motivated primarily by nonhomeostatic cues rather than a
depletion of fuels per se. These include time of day; social sig-
nals; and, importantly, the hedonic attractiveness or palatability
of certain foods. The drive to pursue such pleasurable experi-
ences is largely mediated by the brain reward system.
Food palatability cues, primarily taste and smell, and macro-
nutrient composition (Sclafani and Ackroff, 2012) ultimately
activate brain reward pathways. Taste information passes
through two brainstem relays, the first located in the NTS and
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then bifurcates in the PBN, with information passing from the
PBN to thalamus and onto gustatory cortex to encode taste
discrimination. In contrast, taste information passes from the
PBN to the ventral tegmental area (VTA), via either direct ormulti-
synaptic pathways involving limbic structures (e.g., amygdala/
bed nucleus of the stria terminalis [BNST], hypothalamus, and
medial PFC) to encode food reward. As a result, highly palatable
foods activate dopaminergic neurons in the VTA that project to
the nucleus accumbens (NAc), PFC, and amygdala. This dopa-
minergic system is linked with the motivating or ‘‘wanting’’
component of food reward, promoting behaviors (e.g., food
searching and lever pressing for a reward) that are directed to-
ward reward receipt (Berridge, 2009). In addition, opioidergic
and cannabinoid activity in the NAc is linked with the hedonic
or ‘‘liking’’ component of food reward, promoting increased
pleasure from the consumption of these foods (Berridge, 2009;
Kelley and Berridge, 2002).
Importantly, there is considerable crosstalk between the
homeostatic and reward circuits, mediated by in part by direct
actions of insulin and leptin at their receptors within the cortico-
limbic system, as well as by secondary hypothalamic effector
systems (Davis et al., 2011;Figlewicz et al., 2001, 2004; Hommel
et al., 2006). For example, VTA dopamine neurons expressing
Lepr reduce their firing rate in response to leptin administration.
This is associated with decreased food intake (Hommel et al.,
2006). Conversely, reduced leptin signaling in the midbrain/
VTA heightens behavioral responses to palatable food (Davis
et al., 2011; Hommel et al., 2006). When an animal is food
deprived, circulating leptin and insulin are decreased. Conse-
quently, hedonically pleasing sensations of food become exag-
gerated. This results in more food being eaten, even in the face
of inhibitory signals from the periphery (Ryan et al., 2012).
Stress and the Consumption of Palatable Food
Stress Exerts Divergent Effects on Total Caloric Intake. Stress
exerts bidirectional effects on total caloric intake. When individ-
uals are asked to self-report food intake, for example, approxi-
mately 25%–40% report that they eat less than usual, whereas
35%–60% report that they eat more than usual during stress
(Epel et al., 2004; Oliver and Wardle, 1999; Weinstein et al.,
1997). The reasons for this divergence remain unclear. Current
evidence suggests this apparent bimodal pattern may result
from (1) differences in the nature or intensity of the stressor(s)
involved, with high-intensity stressors more likely to elicit
anorexia whereas milder ‘‘everyday’’ social stressors are associ-
ated with increased food intake; (2) differences in individual’s
prior experience with food; and/or (3) individual differences
in the neuroendocrine and reward responses to stress and/or
food. Limited data from both animal and human studies support
each of these possibilities, though further investigation is
needed.
First, although rodent models of chronic stress have tradition-
ally been associated with decreased total caloric intake, these
paradigms typically include both psychogenic stressors (e.g.,
restraint) and stressors that are primarily physical in nature
(e.g., cold; forced swim) (Ulrich-Lai et al., 2007; Willner et al.,
1996). In contrast, Bartolomucci and colleagues have developed
a model of chronic psychosocial stress in which defeated
subordinate mice consuming a high-fat diet are hyperphagicand become obese (Bartolomucci et al., 2009). Likewise, chronic
psychosocial stress in subordinate female rhesus monkeys is
orexigenic when a high-fat and high-sugar diet is offered (Micho-
poulos et al., 2012). In agreement with this, when considering the
human literature, it is apparent that studies reporting stress-
induced anorexia tend to involve higher-intensity stressors like
military combat or imminent surgery (Bellisle et al., 1990; Popper
et al., 1989), whereas studies reporting stress-induced hyper-
phagia tend to involve daily life stressors like school, work, and
interpersonal relationships (Epel et al., 2001; McCann et al.,
1990; Pollard et al., 1995; Rutters et al., 2009; Wardle et al.,
2000).
Second, stress-induced hyperphagia in humans may occur
predominantly among individuals that self-describe as normally
‘‘restrained’’ or ‘‘emotional’’ eaters (Oliver and Wardle, 1999;
Rutters et al., 2009; Wardle et al., 2000). Specifically, chronic
stress decreases neuronal activation induced by viewing high-
calorie foods in brain regions related to planning and emotional
control (Tryon et al., 2013a), which may predispose to emotional
eating. In agreement with this, stress interferes with behavioral
modifications like ‘‘dieting’’ (reviewed in Calu et al., 2013) and
is associated with disinhibited food intake (Groesz et al., 2012).
Likewise, a rat model that combines acute foot shock stress
with a history of repeated bouts of food restriction meant to
mimic yo-yo dieting increases total caloric intake when palatable
food is made available (Hagan et al., 2002).
Finally, individual differences in the responsiveness of
homeostatic and reward circuits governing energy balance and
stress regulation (discussed above) may predict the effects of
chronic stress on food intake. For example, the stress-induced
rise in circulating leptin during a TSST was negatively associated
with food intake immediately following the stressor (Tomiyama
et al., 2012). In addition, when well-characterized substrains of
diet-resistant and diet-induced obese (DIO) rats were exposed
to 5 weeks of chronic stress together with exposure to a palat-
able diet, DIO rats had significantly diminished HPA and auto-
nomic and metabolic responses to stress (Levin et al., 2000).
Stress Increases Consumption of Palatable Food. Importantly,
stress promotes the choice of calorically dense, highly palatable
foods relative to more nutritious, less-tasty alternatives, poten-
tially contributing to its adverse metabolic effects (Figure 2)
(Groesz et al., 2012; Kim et al., 2013; Laugero et al., 2011;
McCann et al., 1990; Oliver and Wardle, 1999; Tryon et al.,
2013a). This can occur even among people who decrease their
total overall caloric intake (Oliver and Wardle, 1999). Similarly,
when chronically stressed rodents are provided a choice, they
will maintain or increase consumption of sugar or lard despite
decreasing chow intake (Pecoraro et al., 2004; Ulrich-Lai et al.,
2007). Although a history of dietary restraint might facilitate this
behavior, the rodents in these paradigms presumably did not
previously ‘‘restrain’’ their eating behavior. Thus, increasedmoti-
vation to consume palatable foods during stress may also be
important. Consistent with this possibility, stress increases the
willingness of both humans and rodents to work for palatable
food (Lemmens et al., 2011; Willner et al., 1998) and increases
neuronal activation in brain reward and motivation structures
following exposure to palatable foods (Rudenga et al., 2013;
Tryon et al., 2013a). Collectively, these findings support that
stress increases the ‘‘wanting’’ or motivation to obtain highlyCell Metabolism 19, June 3, 2014 ª2014 Elsevier Inc. 915
Figure 2. Schematic Illustrating the Complex Functional
Interactions between Homeostatic Metabolic Signaling,
Physiological Responses to Stress, and Reward-Driven Food Intake
These interactions likely occur, at least in part, as consequence of these
systems’ largely overlapping anatomical circuitry. Metabolic signals, including
leptin and ghrelin, influence reward-driven food intake—which in turn alters
energy balance. These metabolic signals also modulate HPA and autonomic
responses to stress. Moreover, stress mediators can override metabolic
homeostasis to redistribute fuels in the face of a challenge. Finally, stress
mediators like glucocorticoids promote reward-driven food intake, which
reciprocally reduces stress responses. All of these systems are profoundly
influenced by stress exposure. In stress-prone individuals, this results in
increased motivation for food reward and increased intake of highly palatable
foods that in turn limit uncomfortable psychological and physiological re-
sponses to stress. However, over the long term, chronic stress exposure can
contribute to the development of metabolic disease.
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Perspectivepalatable foods, a phenomenon that may be related to food
craving (Willner et al., 1998).
Notably, this increased motivation to consume palatable
foods may occur independently from a decrease in palatable
food ‘‘liking’’ during stress. For instance, stress induces anhe-
donia in rodents in which the intake of weakly preferred sub-
stance (saccharin or dilute sucrose drink), but not highly
preferred substance (concentrated sucrose drink), is reduced
during chronic stress (Sampson et al., 1992; Ulrich-Lai et al.,
2007; Willner et al., 1996). Similarly, experimentally induced
depressed mood in people can reduce the perceived pleasant-
ness of food (Willner and Healy, 1994).
In agreement with the observation that chronic stress promotes
the consumption of palatable food, glucocorticoid receptor
signaling in brain increases caloric intake, particularly of palatable
foods, thereby promoting body weight gain (Green et al., 1992;
Tataranni et al., 1996; Tempel et al., 1992; Zakrzewska et al.,
1999).Moreover, glucocorticoidscontribute tochanges in thesyn-
aptic input organization of AgRP and POMC neurons in the ARC,
favoring increased excitation of AgRP and increased inhibition of
POMC neurons (Gyengesi et al., 2010). Finally, circulating gluco-
corticoid concentration is positively associated with increased
food intake in people (Francis et al., 2013; George et al., 2010)
and saccharin intake in rats (Bhatnagar et al., 2000), supporting
that glucocorticoids increase reward-driven food intake.
The gut hormone ghrelin is also implicated in stress-induced
changes in palatable feeding. In addition to promoting food
intake by its action in homeostatic circuits, ghrelin enhances
the rewarding properties of food via its signaling in the VTA
(Disse et al., 2011; Egecioglu et al., 2010; Perello et al., 2010).916 Cell Metabolism 19, June 3, 2014 ª2014 Elsevier Inc.Using a CSDS paradigm, Zigman and colleagues report that
the CSDS-induced increase in the conditioned place preference
for a high-fat diet, observed in wild-type mice, is absent in
CSDS-exposed GHSR-deficient mice (Chuang et al., 2011).
Furthermore, expression of GHSR in tyrosine-hydroxylase-
containing neurons, including dopaminergic neurons of the
VTA, is permissive for the induction of hedonic feeding elicited
by CSDS (Chuang et al., 2011; Perello´ and Zigman, 2012).
Food Reward and Stress Reactivity
Colloquial wisdom suggests that individuals increase their rela-
tive intake of palatable foods during chronic stress as a mecha-
nism for self-soothing. In other words, ingestion of so-called
‘‘comfort-foods’’ is thought to blunt unpleasant physiological re-
sponses to stress (Figure 2) (Dallman et al., 2003; Gibson, 2006).
In agreement with this possibility, palatable food intake improves
mood and decreases perceived stress and plasma glucocorti-
coid levels in people (Gibson, 2006; Macht and Mueller, 2007;
Tomiyama et al., 2011; Tryon et al., 2013b), particularly those
with high stress proneness (Markus et al., 2000). Similarly, ro-
dents that are provided the option of consuming palatable
foods like sucrose and lard have reduced CRH mRNA expres-
sion in the PVN, accompanied by blunted HPA and sympathetic
and behavioral responses to acute stress (la Fleur et al., 2005;
Pecoraro et al., 2004; Shide and Blass, 1989; Strack et al.,
1997; Ulrich-Lai et al., 2007, 2010). At least some of the stress-
relieving effects of consuming such palatable food results from
its pleasurable and rewarding properties (Barr et al., 1999; Macht
and Mueller, 2007; Ulrich-Lai et al., 2010), though caloric and
macronutrient composition likely also play a role (Laugero
et al., 2001). For example, when rats with free access to normal
chow and water are given additional brief, twice-daily access to
a limited amount of sucrose drink, both plasma corticosterone
and tachycardic responses to restraint are attenuated, and anx-
iety-like behavior is reduced. Brief, twice-daily access to the
noncaloric sweetener saccharin replicates this stress relief, indi-
cating the pleasurable and rewarding properties are sufficient
to elicit these effects. Moreover, delivering sucrose by intragas-
tric gavage, which provides its postingestive consequences
while minimizing taste and palatability, does not provide stress
relief, suggesting the hedonic and rewarding properties are
necessary as well as sufficient in this model (Ulrich-Lai et al.,
2010). Importantly, lesions of the basolateral amygdala prevent
the stress blunting provided by limited sucrose access, impli-
cating this structure as a critical link between the reward and
stress systems in this model (Ulrich-Lai et al., 2010). Additional
studies will be necessary to understand the relative importance
of food reward and other postingestive consequences of
palatable food consumption in other ‘‘comfort-feeding’’ models,
including stress-associated high-fat diet feeding.
Therapeutic Implications
Pharmacology
In light of the substantial overlap between neuroendocrine
circuits regulating energy balance and stress responses, it is
perhaps not surprising that therapeutic interventions targeting
either metabolic disease or stress-associated mood disorders
have been beset by reciprocal unintended side effects. Con-
sistent with previous reports (Berken et al., 1984; Raeder et al.,
2006), for example, a recent study demonstrates that users of
Table 2. Neuropsychiatric Effects of CNS-Acting Drugs Prescribed for Weight Loss
Drug
Molecular Mechanism
of Action Effects on Stress Regulatory Systems Evidence for Neuropsychiatric Effects
Bupropion NE and DA reuptake
inhibitor
Decreased HPA axis activity (Viana et al., 2008) In clinical use as an antidepressant
Ecopipam D1/D5-receptor
antagonist
Increased SAM activity (Zheng et al., 2013) Depression, anxiety, and suicidal ideation
(Astrup et al., 2007)
Fenfluramine Increases 5HT
release
Increased HPA axis activity (Heisler et al., 2007);
increased SAM activity (Bray, 2000)
Increased ‘‘CNS complaints’’ (this included insomnia,
nervousness, depression, fatigue, and increased
dreaming) (Weintraub et al., 1984)
Liraglutide GLP-1R agonist GLP1R signaling increased HPA axis activity
(Kinzig et al., 2003; Larsen et al., 1997) and
increased SAM activity (Yamamoto et al., 2002)
Limited evidence for modestly increased incidence
of ‘‘psychiatric disorders’’ (this included insomnia,
depressed mood, and nervousness) (Astrup et al.,
2009)
Lorcaserin 5HT2c receptor
agonist
5HT2c activation increased HPA axis activity
(Heisler et al., 2007)
Fatigue (Fidler et al., 2011; Smith et al., 2010)
Naltrexone Opioid-receptor
antagonist
Increased HPA axis activity
(Eisenberg, 1984; O’Malley et al., 2002)
Fatigue and sleepiness; limited evidence for mild
depression/dysphoria and nervousness/anxiety
(Atkinson et al., 1985; Hollister et al., 1981;
Mendelson et al., 1978); no mood effects observed
in combination with bupropion (Greenway et al.,
2009, 2010)
Phentermine Increases
NE release
Increased SAM activity (Bays, 2010) Increased ‘‘CNS complaints’’ (this category included
insomnia, nervousness, depression, fatigue, and
increased dreaming) (Weintraub et al., 1984); anxiety,
irritability, and disturbance in attention when given in
combination with Topiramate (Gadde et al., 2011)
Rimonabant/
Taranabant
CB1 receptor
antagonist/
inverse agonist
Loss of CB1 receptor signaling increased HPA axis
activity (Cota, 2008; Evanson et al., 2010; Hill
and McEwen, 2010) and increased SAM activity
(Bellocchio et al., 2013; Quarta et al., 2010)
Depression, anxiety, and suicidal ideation
(Christensen et al., 2007; Van Gaal et al., 2005)
Sibutramine NE and 5HT reuptake
inhibitor
Increased SAM activity (Bray, 2000) Insomnia (Bray et al., 1996)
Tesofensine NE, DA, and 5HT
reuptake inhibitor
Increased SAM activity (Bentzen et al., 2013) Insomnia; anger and hostility at high doses
(Astrup et al., 2008)
Topiramate Not well understood Reduced HPA axis activity (York et al., 2000) Cognitive impairment, nervousness, depression,
and mood problems (Bray et al., 2003; Wilding
et al., 2004); anxiety, irritability, and disturbance
in attention when given in combination Phentermine
(Gadde et al., 2011)
Pharmacological weight loss treatments are associated with altered HPA and SAM activity and in certain cases may increase risk of other neuropsy-
chiatric effects in some individuals.
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pressant medications gain significantly more weight compared
to nonusers matched for depression-related characteristics.
This was accompanied by a doubling of the risk of diagnosed
type 2 diabetes (Kivima¨ki et al., 2010).
Conversely, pharmacological interventions in development for
the treatment of obesity have been undermined by unintended
psychological/behavioral consequences. Several of the CNS-
acting drugs that have been used for weight loss have behavioral
effects beyond their influence on energy balance (see Table 2).
For example, endocannabinoid receptor (CB1) signaling in both
homeostatic and reward circuitry increases homeostatic and
hedonic aspects of food intake (reviewed by Silvestri and Di
Marzo, 2013). In agreement with this, CB1 antagonists are effec-
tive to elicitweight lossandhadbeenprescribed for the treatment
of obesity. Unfortunately, however, the CB1 antagonist Rimona-bant was withdrawn from the European market in 2009, and was
not approved for in the U.S., because its use was associated
with a significant increase in symptoms of depression, anxiety,
and suicidal ideation (Christensen et al., 2007; Van Gaal et al.,
2005). Phase III trials of the CB1 inverse agonist Taranabant
were stopped due to similar side effects (Aronne et al., 2010).
As another example, the dopamine (D1/D5) receptor antagonist
Ecopipam produced 3.1%–4.3% greater weight loss than pla-
cebo in phase III studies, consistentwith the role of dopaminergic
signaling to increase appetitive motivation and palatable food
preference (El-Ghundi et al., 2003; Yu et al., 2000). However,
these trials were discontinued due to unexpected adverse
psychiatric effects, again including increased incidence of
depression, anxiety, and suicidal ideation (Astrup et al., 2007).
Such behavioral effects of centrally acting antiobesity agents
may occur because the targeted receptors and circuits notCell Metabolism 19, June 3, 2014 ª2014 Elsevier Inc. 917
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pathways. Moreover, plasticity in these circuits occurring over
periods of chronic stress, discussed above, may contribute to
heterogeneity in the psychobehavioral responses to CNS-acting
weight loss drugs. That is, an individual’s ongoing, and history of,
stress exposure may modulate his/her behavioral response to
these treatments. For example, CB1 signaling in stress-regulato-
ry circuits inhibits physiological responses to acute stress and
may facilitate brain adaptations to chronic stress (reviewed by
Bermudez-Silva et al., 2012; Cota, 2008; Gorzalka and Dang,
2012). Importantly, repeat stress exposure affects various
aspects of the endocannabinoid system including the following:
concentration of the major endocannabinoids, activities of their
degrading enzymes, agonist binding properties of receptors,
and receptor-mediated control of neurotransmitter release (Bor-
tolato et al., 2007; Dubreucq et al., 2012; Hill et al., 2005; Patel
and Hillard, 2008; Reich et al., 2009). All of these changes may
interact with CB1-targeted drug treatments to influence psycho-
behavioral responses. Similarly, stress-induced increases in
NAc DA release depend on the type, duration, novelty, and
controllability of the stress exposure (Cabib and Puglisi-Allegra,
2012). Therefore, an individual’s recent and ongoing experience
with psychological stressors may alter his/her response to dopa-
mine receptor antagonists like Ecopipam, perhaps contributing
to the varying presentation of psychobehavioral side effects.
Relevant to this, we note that dieting itself can be a significant
stressor and that repeated episodes of dieting and weight loss
may represent a form of chronic stress. As early as 1957, for
example, A.J. Stunkard began documenting the incidence of
anxiety, depression, and ‘‘emotional upset’’ among a subset of
individuals during weight loss achieved by enforced caloric
restriction (Stunkard, 1957). Likewise, a mild caloric restriction
paradigm, inducing 10%–15% weight loss over 3 weeks,
potently increased HPA responsivity to a novel stressor in mice
and increased depression-like behavior in the tail suspension
test. This was associated with brain-region-specific alterations
of corticotropin-releasing-factor expression and promoter
methylation (Pankevich et al., 2010). Such findings raise the
possibility that an individual’s history of dieting may alter brain
homeostatic, stress, and reward circuitry in a way that impacts
key molecular targets of weight loss drugs, resulting in variable
behavioral responses to these drugs.
Finally, it is important to note that at least some of the CNS-
acting drugs that have been prescribed for weight loss are
thought to have a relatively low risk profile for adverse neuro-
psychiatric events, and some may even improve mood. These
include some of the various drugs known to increasemonoamine
neurotransmission directly, like bupropion, lorcaserin, and si-
butramine (Nathan et al., 2011).
The link between CNS-acting weight loss drugs and unin-
tended mood effects has led some to suggest that ongoing
efforts should target peripherally acting mechanisms. For ex-
ample, action at peripheral CB1 receptors is thought to con-
tribute significantly to the metabolic benefits of CB1 antagonists
(Kunos and Tam, 2011; Need et al., 2006; Nogueiras et al., 2008).
Indeed, new CB1 compounds with limited CNS penetration
are still effective in reducing body weight and improving insulin
resistance, perhaps by reducing plasma leptin levels and revers-
ing leptin resistance (Tam et al., 2012). Thus, there is hope that918 Cell Metabolism 19, June 3, 2014 ª2014 Elsevier Inc.such compounds may avoid the psychobehavioral responses
previously observed with this class of drugs. Other peripheral
strategies in varying phases of development include targeting
intestinal digestion and uptake of lipids (e.g., Orlistat and
Cetilistat) (Kopelman et al., 2010; Torgerson et al., 2004), bile
acid signaling (Thomas et al., 2008), and BAT thermogenesis
(Fru¨hbeck et al., 2009). Although strategies focusing on periph-
eral targets may indeed promote fewer psychobehavioral side
effects, we caution that even strictly peripheral interventions
may indirectly impinge on CNS stress and reward circuitry due,
for example, to consequent changes in CNS-acting adiposity
and satiation signals.
Surgery
Bariatric surgical procedures like Roux-en-y gastric bypass and
vertical sleeve gastrectomy are currently the most durable and
effective treatment for obesity and associated metabolic disor-
ders. Increasing evidence demonstrates that the efficacy of
these procedures is not derived primarily from their potentially
restrictive and/or malabsorptive anatomical effects. Rather, it
is now appreciated that these benefits result from alterations
in neurohumoral signals arising in the gut that may act in the
brain and elsewhere to alter energy balance. These include, for
example, substantial changes in circulating gut hormones like
ghrelin, GLP-1, and CCK (reviewed by Stefater et al., 2012). In
light of the overlap between neuroendocrine circuits governing
energy balance and stress reactivity (discussed above), changes
in these peripheral ‘‘metabolic’’ signals may also alter stress
regulation and influence the etiology of stress-related mood dis-
orders following bariatric procedures. Relevant to this, current
evidence largely indicates an improvement in postoperative
indices of depression (Karlsson et al., 2003; Papageorgiou
et al., 2002; Stunkard andWadden, 1992). However, enthusiasm
for this apparent benefit is tempered by a recent meta-analysis
suggesting risk of completed suicide may be increased after
bariatric surgery (Peterha¨nsel et al., 2013). Additional study is
clearly needed. Given the psychosocial and cultural implica-
tions of obesity and weight loss in human subjects, metabolic
and behavioral studies in appropriate animal models can provide
a needed complement to clinical investigations by focusing
directly on underlying molecular and physiological mechanisms.Summary and Conclusions
Metabolic disease and stress-related disorders are thought to
be significantly comorbid. Likewise, energy balance and stress
regulation are mediated by largely overlapping neural circuits,
indicating important functional interactions between these sys-
tems. Consistent with this prediction, neuroendocrine signals
that regulate energy balance are now appreciated to influence
stress regulation. Conversely, stress responses have clear influ-
ence on food intake, energy expenditure, and adiposity. These
interrelationships have important therapeutic implications,
underscoring the importance of assessing the stress regulatory
effects of potential metabolic therapies, as well as the metabolic
consequences of potential therapies for stress-related disorders.ACKNOWLEDGMENTS
The authors are supported by the NIH (HL111319 to K.K.R.; DK091425
to Y.M.U.).
Cell Metabolism
PerspectiveREFERENCES
Adan, R.A.H., Vanderschuren, L.J.M.J., and la Fleur, S.E. (2008). Anti-obesity
drugs and neural circuits of feeding. Trends Pharmacol. Sci. 29, 208–217.
Akana, S.F., Dallman, M.F., Bradbury, M.J., Scribner, K.A., Strack, A.M., and
Walker, C.D. (1992). Feedback and facilitation in the adrenocortical system:
unmasking facilitation by partial inhibition of the glucocorticoid response to
prior stress. Endocrinology 131, 57–68.
Anderson, R.J., Freedland, K.E., Clouse, R.E., and Lustman, P.J. (2001). The
prevalence of comorbid depression in adults with diabetes: a meta-analysis.
Diabetes Care 24, 1069–1078.
Andre, J., Zeau, B., Pohl, M., Cesselin, F., Benoliel, J.-J., and Becker, C.
(2005). Involvement of cholecystokininergic systems in anxiety-induced hyper-
algesia in male rats: behavioral and biochemical studies. J. Neurosci. 25,
7896–7904.
Andrews, Z.B., Liu, Z.-W., Walllingford, N., Erion, D.M., Borok, E., Friedman,
J.M., Tscho¨p, M.H., Shanabrough, M., Cline, G., Shulman, G.I., et al. (2008).
UCP2 mediates ghrelin’s action on NPY/AgRP neurons by lowering free radi-
cals. Nature 454, 846–851.
Arner, P. (1995). Differences in lipolysis between human subcutaneous and
omental adipose tissues. Ann. Med. 27, 435–438.
Aronne, L.J., Tonstad, S., Moreno, M., Gantz, I., Erondu, N., Suryawanshi, S.,
Molony, C., Sieberts, S., Nayee, J., Meehan, A.G., et al. (2010). A clinical trial
assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in
obese and overweight patients: a high-dose study. Int. J. Obes. (Lond.) 34,
919–935.
Asakawa, A., Inui, A., Kaga, T., Yuzuriha, H., Nagata, T., Fujimiya, M., Kat-
suura, G., Makino, S., Fujino, M.A., and Kasuga, M. (2001). A role of ghrelin
in neuroendocrine and behavioral responses to stress in mice. Neuroendocri-
nology 74, 143–147.
Astrup, A., Greenway, F.L., Ling, W., Pedicone, L., Lachowicz, J., Strader,
C.D., and Kwan, R.; Ecopipam Obesity Study Group (2007). Randomized
controlled trials of the D1/D5 antagonist ecopipam for weight loss in obese
subjects. Obesity (Silver Spring) 15, 1717–1731.
Astrup, A., Madsbad, S., Breum, L., Jensen, T.J., Kroustrup, J.P., and Larsen,
T.M. (2008). Effect of tesofensine on bodyweight loss, body composition, and
quality of life in obese patients: a randomised, double-blind, placebo-
controlled trial. Lancet 372, 1906–1913.
Astrup, A., Ro¨ssner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M.,
Madsen, J., Rasmussen, M.F., and Lean, M.E.; NN8022-1807 Study Group
(2009). Effects of liraglutide in the treatment of obesity: a randomised, dou-
ble-blind, placebo-controlled study. Lancet 374, 1606–1616.
Atkinson, R.L., Berke, L.K., Drake, C.R., Bibbs,M.L.,Williams, F.L., and Kaiser,
D.L. (1985). Effects of long-term therapy with naltrexone on body weight in
obesity. Clin. Pharmacol. Ther. 38, 419–422.
Baggio, L.L., and Drucker, D.J. (2007). Biology of incretins: GLP-1 and GIP.
Gastroenterology 132, 2131–2157.
Barr, R.G., Pantel, M.S., Young, S.N., Wright, J.H., Hendricks, L.A., and
Gravel, R. (1999). The response of crying newborns to sucrose: is it a ‘‘sweet-
ness’’ effect? Physiol. Behav. 66, 409–417.
Bartness, T.J., and Song, C.K. (2007). Thematic review series: adipocyte
biology. Sympathetic and sensory innervation of white adipose tissue.
J. Lipid Res. 48, 1655–1672.
Bartolomucci, A., Cabassi, A., Govoni, P., Ceresini, G., Cero, C., Berra, D.,
Dadomo, H., Franceschini, P., Dell’Omo, G., Parmigiani, S., and Palanza, P.
(2009). Metabolic consequences and vulnerability to diet-induced obesity in
male mice under chronic social stress. PLoS ONE 4, e4331.
Baxter, J.D. (1976). Glucocorticoid hormone action. Pharmacol. Ther. B. 2,
605–669.
Bays, H. (2010). Phentermine, topiramate and their combination for the
treatment of adiposopathy (‘sick fat’) and metabolic disease. Expert Rev.
Cardiovasc. Ther. 8, 1777–1801.
Becker, C., Zeau, B., Rivat, C., Blugeot, A., Hamon, M., and Benoliel, J.-J.
(2008). Repeated social defeat-induced depression-like behavioral and bio-logical alterations in rats: involvement of cholecystokinin. Mol. Psychiatry 13,
1079–1092.
Beinfeld, M.C. (2001). An introduction to neuronal cholecystokinin. Peptides
22, 1197–1200.
Bellisle, F., Louis-Sylvestre, J., Linet, N., Rocaboy, B., Dalle, B., Cheneau, F.,
L’Hinoret, D., and Guyot, L. (1990). Anxiety and food intake in men. Psycho-
som. Med. 52, 452–457.
Bellocchio, L., Soria-Go´mez, E., Quarta, C., Metna-Laurent, M., Cardinal, P.,
Binder, E., Cannich, A., Delamarre, A., Ha¨ring, M., Martı´n-Fontecha, M.,
et al. (2013). Activation of the sympathetic nervous systemmediates hypopha-
gic and anxiety-like effects of CB1 receptor blockade. Proc. Natl. Acad. Sci.
USA 110, 4786–4791.
Benoit, S.C., Air, E.L., Coolen, L.M., Strauss, R., Jackman, A., Clegg, D.J.,
Seeley, R.J., and Woods, S.C. (2002). The catabolic action of insulin in the
brain is mediated by melanocortins. J. Neurosci. 22, 9048–9052.
Bentzen, B.H., Grunnet, M., Hyveled-Nielsen, L., Sundgreen, C., Lassen, J.B.,
and Hansen, H.H. (2013). Anti-hypertensive treatment preserves appetite
suppression while preventing cardiovascular adverse effects of tesofensine
in rats. Obesity (Silver Spring) 21, 985–992.
Berken, G.H., Weinstein, D.O., and Stern, W.C. (1984). Weight gain. A side-
effect of tricyclic antidepressants. J. Affect. Disord. 7, 133–138.
Bermudez-Silva, F.J., Cardinal, P., and Cota, D. (2012). The role of the
endocannabinoid system in the neuroendocrine regulation of energy balance.
J. Psychopharmacol. (Oxford) 26, 114–124.
Berridge, K.C. (2009). ‘Liking’ and ‘wanting’ food rewards: brain substrates
and roles in eating disorders. Physiol. Behav. 97, 537–550.
Bhatnagar, S., Bell, M.E., Liang, J., Soriano, L., Nagy, T.R., and Dallman, M.F.
(2000). Corticosterone facilitates saccharin intake in adrenalectomized
rats: does corticosterone increase stimulus salience? J. Neuroendocrinol.
12, 453–460.
Bohringer, A., Schwabe, L., Richter, S., and Schachinger, H. (2008). Intranasal
insulin attenuates the hypothalamic-pituitary-adrenal axis response to
psychosocial stress. Psychoneuroendocrinology 33, 1394–1400.
Bortolato,M., Mangieri, R.A., Fu, J., Kim, J.H., Arguello, O., Duranti, A., Tontini,
A., Mor, M., Tarzia, G., and Piomelli, D. (2007). Antidepressant-like activity of
the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic
mild stress. Biol. Psychiatry 62, 1103–1110.
Bray, G.A. (2000). Reciprocal relation of food intake and sympathetic activity:
experimental observations and clinical implications. Int. J. Obes. Relat. Metab.
Disord. 24 (Suppl 2 ), S8–S17.
Bray, G.A., Ryan, D.H., Gordon, D., Heidingsfelder, S., Cerise, F., and Wilson,
K. (1996). A double-blind randomized placebo-controlled trial of sibutramine.
Obes. Res. 4, 263–270.
Bray, G.A., Hollander, P., Klein, S., Kushner, R., Levy, B., Fitchet, M., and
Perry, B.H. (2003). A 6-month randomized, placebo-controlled, dose-ranging
trial of topiramate for weight loss in obesity. Obes. Res. 11, 722–733.
Cabib, S., and Puglisi-Allegra, S. (2012). The mesoaccumbens dopamine in
coping with stress. Neurosci. Biobehav. Rev. 36, 79–89.
Cabral, A., Suescun, O., Zigman, J.M., and Perello, M. (2012). Ghrelin indirectly
activates hypophysiotropic CRF neurons in rodents. PLoS ONE 7, e31462.
Calu, D.J., Chen, Y.-W., Kawa, A.B., Nair, S.G., and Shaham, Y. (2013). The
use of the reinstatement model to study relapse to palatable food seeking
during dieting. Neuropharmacology 76, 395–406.
Campbell, J.E., Peckett, A.J., D’souza, A.M., Hawke, T.J., and Riddell, M.C.
(2011). Adipogenic and lipolytic effects of chronic glucocorticoid exposure.
Am. J. Physiol. Cell Physiol. 300, C198–C209.
Carlini, V.P., Monzo´n, M.E., Varas, M.M., Cragnolini, A.B., Schio¨th, H.B., Sci-
monelli, T.N., and de Barioglio, S.R. (2002). Ghrelin increases anxiety-like
behavior and memory retention in rats. Biochem. Biophys. Res. Commun.
299, 739–743.
Carlini, V.P., Varas, M.M., Cragnolini, A.B., Schio¨th, H.B., Scimonelli, T.N., and
de Barioglio, S.R. (2004). Differential role of the hippocampus, amygdala,
and dorsal raphe nucleus in regulating feeding, memory, and anxiety-likeCell Metabolism 19, June 3, 2014 ª2014 Elsevier Inc. 919
Cell Metabolism
Perspectivebehavioral responses to ghrelin. Biochem. Biophys. Res. Commun. 313,
635–641.
Christensen, R., Kristensen, P.K., Bartels, E.M., Bliddal, H., and Astrup, A.
(2007). Efficacy and safety of the weight-loss drug rimonabant: a meta-anal-
ysis of randomised trials. Lancet 370, 1706–1713.
Chuang, J.C., and Zigman, J.M. (2010). Ghrelin’s roles in stress, mood, and
anxiety regulation. Int. J. Pept. 2010.
Chuang, J.-C., Krishnan, V., Yu, H.G., Mason, B., Cui, H., Wilkinson, M.B., Zig-
man, J.M., Elmquist, J.K., Nestler, E.J., and Lutter, M. (2010). A beta3-adren-
ergic-leptin-melanocortin circuit regulates behavioral and metabolic changes
induced by chronic stress. Biol. Psychiatry 67, 1075–1082.
Chuang, J., Perello, M., Sakata, I., Osborne-lawrence, S., Savitt, J.M., Lutter,
M., and Zigman, J.M. (2011). Ghrelin mediates stress-induced food-reward
behavior in mice. J. Clin. Invest. 121, 2684–2692.
Cone, R.D. (2005). Anatomy and regulation of the central melanocortin system.
Nat. Neurosci. 8, 571–578.
Cota, D. (2008). The role of the endocannabinoid system in the regu-
lation of hypothalamic-pituitary-adrenal axis activity. J. Neuroendocrinol. 20
(Suppl 1 ), 35–38.
Cowley, M.A., Smart, J.L., Rubinstein, M., Cerda´n, M.G., Diano, S., Horvath,
T.L., Cone, R.D., and Low, M.J. (2001). Leptin activates anorexigenic POMC
neurons through a neural network in the arcuate nucleus. Nature 411, 480–484.
Cowley, M.A., Smith, R.G., Diano, S., Tscho¨p, M., Pronchuk, N., Grove, K.L.,
Strasburger, C.J., Bidlingmaier, M., Esterman, M., Heiman, M.L., et al.
(2003). The distribution and mechanism of action of ghrelin in the CNS demon-
strates a novel hypothalamic circuit regulating energy homeostasis. Neuron
37, 649–661.
Coyne, J.C., and Downey, G. (1991). Social factors and psychopathology:
stress, social support, and coping processes. Annu. Rev. Psychol. 42,
401–425.
da Silva, A.A., Tallam, L.S., Liu, J., and Hall, J.E. (2006). Chronic antidiabetic
and cardiovascular actions of leptin: role of CNS and increased adrenergic ac-
tivity. Am. J. Physiol. Regul. Integr. Comp. Physiol. 291, R1275–R1282.
Dallman, M.F., Pecoraro, N., Akana, S.F., La Fleur, S.E., Gomez, F., Houshyar,
H., Bell, M.E., Bhatnagar, S., Laugero, K.D., and Manalo, S. (2003). Chronic
stress and obesity: a new view of ‘‘comfort food’’. Proc. Natl. Acad. Sci.
USA 100, 11696–11701.
Davis, S.N., Colburn, C., Dobbins, R., Nadeau, S., Neal, D., Williams, P., and
Cherrington, A.D. (1995). Evidence that the brain of the conscious dog is insulin
sensitive. J. Clin. Invest. 95, 593–602.
Davis, J.F., Choi, D.L., Schurdak, J.D., Fitzgerald, M.F., Clegg, D.J., Lipton,
J.W., Figlewicz, D.P., and Benoit, S.C. (2011). Leptin regulates energy balance
and motivation through action at distinct neural circuits. Biol. Psychiatry 69,
668–674.
de Kloet, E.R., Joe¨ls, M., and Holsboer, F. (2005). Stress and the brain: from
adaptation to disease. Nat. Rev. Neurosci. 6, 463–475.
de Montigny, C. (1989). Cholecystokinin tetrapeptide induces panic-like at-
tacks in healthy volunteers. Preliminary findings. Arch. Gen. Psychiatry 46,
511–517.
Dhillo, W.S., Small, C.J., Seal, L.J., Kim, M.-S., Stanley, S.A., Murphy, K.G.,
Ghatei, M.A., and Bloom, S.R. (2002). The hypothalamic melanocortin system
stimulates the hypothalamo-pituitary-adrenal axis in vitro and in vivo in male
rats. Neuroendocrinology 75, 209–216.
Diggs-Andrews, K.A., Zhang, X., Song, Z., Daphna-Iken, D., Routh, V.H., and
Fisher, S.J. (2010). Brain insulin action regulates hypothalamic glucose
sensing and the counterregulatory response to hypoglycemia. Diabetes 59,
2271–2280.
Disse, E., Bussier, A.L., Deblon, N., Pfluger, P.T., Tscho¨p, M.H., Laville, M.,
and Rohner-Jeanrenaud, F. (2011). Systemic ghrelin and reward: effect of
cholinergic blockade. Physiol. Behav. 102, 481–484.
do Carmo, J.M., da Silva, A.A., Cai, Z., Lin, S., Dubinion, J.H., and Hall, J.E.
(2011). Control of blood pressure, appetite, and glucose by leptin in mice lack-
ing leptin receptors in proopiomelanocortin neurons. Hypertension 57,
918–926.920 Cell Metabolism 19, June 3, 2014 ª2014 Elsevier Inc.Dubreucq, S., Matias, I., Cardinal, P., Ha¨ring, M., Lutz, B., Marsicano, G., and
Chaouloff, F. (2012). Genetic dissection of the role of cannabinoid type-1
receptors in the emotional consequences of repeated social stress in mice.
Neuropsychopharmacology 37, 1885–1900.
Egecioglu, E., Jerlhag, E., Salome´, N., Skibicka, K.P., Haage, D., Bohlooly-Y,
M., Andersson, D., Bjursell, M., Perrissoud, D., Engel, J.A., and Dickson, S.L.
(2010). Ghrelin increases intake of rewarding food in rodents. Addict. Biol. 15,
304–311.
Eisenberg, R.M. (1984). Effects of naltrexone on plasma corticosterone in
opiate-naive rats: a central action. Life Sci. 34, 1185–1191.
El-Ghundi, M., O’Dowd, B.F., Erclik, M., and George, S.R. (2003). Attenuation
of sucrose reinforcement in dopamine D1 receptor deficient mice. Eur. J. Neu-
rosci. 17, 851–862.
Ellacott, K.L.J., and Cone, R.D. (2004). The central melanocortin system and
the integration of short- and long-term regulators of energy homeostasis.
Recent Prog. Horm. Res. 59, 395–408.
Epel, E., Lapidus, R., McEwen, B., and Brownell, K. (2001). Stress may add
bite to appetite in women: a laboratory study of stress-induced cortisol and
eating behavior. Psychoneuroendocrinology 26, 37–49.
Epel, E., Jimenez, S., Brownell, K., Stroud, L., Stoney, C., and Niaura, R.
(2004). Are stress eaters at risk for the metabolic syndrome? Ann. N Y Acad.
Sci. 1032, 208–210.
Evanson, N.K., Tasker, J.G., Hill, M.N., Hillard, C.J., and Herman, J.P. (2010).
Fast feedback inhibition of the HPA axis by glucocorticoids is mediated by
endocannabinoid signaling. Endocrinology 151, 4811–4819.
Faith, M.S., Matz, P.E., and Jorge, M.A. (2002). Obesity-depression associa-
tions in the population. J. Psychosom. Res. 53, 935–942.
Fidler, M.C., Sanchez, M., Raether, B., Weissman, N.J., Smith, S.R., Shana-
han, W.R., and Anderson, C.M.; BLOSSOM Clinical Trial Group (2011).
A one-year randomized trial of lorcaserin for weight loss in obese and over-
weight adults: the BLOSSOM trial. J. Clin. Endocrinol. Metab. 96, 3067–3077.
Figlewicz, D.P., Higgins, M.S., Ng-Evans, S.B., and Havel, P.J. (2001).
Leptin reverses sucrose-conditioned place preference in food-restricted
rats. Physiol. Behav. 73, 229–234.
Figlewicz, D.P., Bennett, J., Evans, S.B., Kaiyala, K., Sipols, A.J., and Benoit,
S.C. (2004). Intraventricular insulin and leptin reverse place preference condi-
tioned with high-fat diet in rats. Behav. Neurosci. 118, 479–487.
Fisher, S.J., Bru¨ning, J.C., Lannon, S., and Kahn, C.R. (2005). Insulin signaling
in the central nervous system is critical for the normal sympathoadrenal
response to hypoglycemia. Diabetes 54, 1447–1451.
Flak, J.N., Ostrander, M.M., Tasker, J.G., and Herman, J.P. (2009). Chronic
stress-induced neurotransmitter plasticity in the PVN. J. Comp. Neurol. 517,
156–165.
Flint, A., Raben, A., Astrup, A., and Holst, J.J. (1998). Glucagon-like peptide 1
promotes satiety and suppresses energy intake in humans. J. Clin. Invest. 101,
515–520.
Francis, L.A., Granger, D.A., and Susman, E.J. (2013). Adrenocortical regula-
tion, eating in the absence of hunger and BMI in young children. Appetite
64, 32–38.
Fruehwald-Schultes, B., Kern, W., Bong, W., Wellhoener, P., Kerner, W., Born,
J., Fehm, H.L., and Peters, A. (1999). Supraphysiological hyperinsulinemia
acutely increases hypothalamic-pituitary-adrenal secretory activity in humans.
J. Clin. Endocrinol. Metab. 84, 3041–3046.
Fru¨hbeck, G., Becerril, S., Sa´inz, N., Garrastachu, P., and Garcı´a-Velloso, M.J.
(2009). BAT: a new target for human obesity? Trends Pharmacol. Sci. 30,
387–396.
Gadde, K.M., Allison, D.B., Ryan, D.H., Peterson, C.A., Troupin, B., Schwiers,
M.L., and Day, W.W. (2011). Effects of low-dose, controlled-release, phenter-
mine plus topiramate combination on weight and associated comorbidities in
overweight and obese adults (CONQUER): a randomised, placebo-controlled,
phase 3 trial. Lancet 377, 1341–1352.
Gariepy, G., Nitka, D., and Schmitz, N. (2010). The association between
obesity and anxiety disorders in the population: a systematic review and
meta-analysis. Int. J. Obes. (Lond.) 34, 407–419.
Cell Metabolism
PerspectiveGarza, J.C., Guo,M., Zhang,W., and Lu, X.-Y. (2012). Leptin restores adult hip-
pocampal neurogenesis in a chronic unpredictable stressmodel of depression
and reverses glucocorticoid-induced inhibition of GSK-3b/b-catenin signaling.
Mol. Psychiatry 17, 790–808.
George, S.A., Khan, S., Briggs, H., and Abelson, J.L. (2010). CRH-stimulated
cortisol release and food intake in healthy, non-obese adults. Psychoneuroen-
docrinology 35, 607–612.
Ghosal, S., Myers, B., and Herman, J.P. (2013). Role of central glucagon-like
peptide-1 in stress regulation. Physiol. Behav. 122, 201–207.
Gibbs, J., and Smith, G.P. (1977). Cholecystokinin and satiety in rats and
rhesus monkeys. Am. J. Clin. Nutr. 30, 758–761.
Gibson, E.L. (2006). Emotional influences on food choice: sensory, physiolog-
ical and psychological pathways. Physiol. Behav. 89, 53–61.
Gorzalka, B.B., and Dang, S.S. (2012). Minireview: Endocannabinoids and
gonadal hormones: bidirectional interactions in physiology and behavior.
Endocrinology 153, 1016–1024.
Green, P.K., Wilkinson, C.W., andWoods, S.C. (1992). Intraventricular cortico-
sterone increases the rate of body weight gain in underweight adrenalecto-
mized rats. Endocrinology 130, 269–275.
Greenfield, J.R., Miller, J.W., Keogh, J.M., Henning, E., Satterwhite, J.H.,
Cameron, G.S., Astruc, B., Mayer, J.P., Brage, S., See, T.C., et al. (2009).
Modulation of blood pressure by central melanocortinergic pathways.
N. Engl. J. Med. 360, 44–52.
Greenway, F.L., Dunayevich, E., Tollefson, G., Erickson, J., Guttadauria, M.,
Fujioka, K., and Cowley, M.A.; NB-201 Study Group (2009). Comparison of
combined bupropion and naltrexone therapy for obesity with monotherapy
and placebo. J. Clin. Endocrinol. Metab. 94, 4898–4906.
Greenway, F.L., Fujioka, K., Plodkowski, R.A., Mudaliar, S., Guttadauria, M.,
Erickson, J., Kim, D.D., and Dunayevich, E.; COR-I Study Group (2010). Effect
of naltrexone plus bupropion on weight loss in overweight and obese adults
(COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase
3 trial. Lancet 376, 595–605.
Griffioen, K.J., Wan, R., Okun, E., Wang, X., Lovett-Barr, M.R., Li, Y., Mughal,
M.R., Mendelowitz, D., and Mattson, M.P. (2011). GLP-1 receptor stimulation
depresses heart rate variability and inhibits neurotransmission to cardiac vagal
neurons. Cardiovasc. Res. 89, 72–78.
Grill, H.J. (2006). Distributed neural control of energy balance: contributions
from hindbrain and hypothalamus. Obesity (Silver Spring) 14 (Suppl 5 ),
216S–221S.
Grill, H.J., and Hayes, M.R. (2012). Hindbrain neurons as an essential hub in
the neuroanatomically distributed control of energy balance. Cell Metab. 16,
296–309.
Grippo, A.J., Moffitt, J.A., and Johnson, A.K. (2002). Cardiovascular alterations
and autonomic imbalance in an experimental model of depression. Am. J.
Physiol. Regul. Integr. Comp. Physiol. 282, R1333–R1341.
Groesz, L.M., McCoy, S., Carl, J., Saslow, L., Stewart, J., Adler, N., Laraia, B.,
and Epel, E. (2012). What is eating you? Stress and the drive to eat. Appetite
58, 717–721.
Gyengesi, E., Liu, Z.-W., D’Agostino, G., Gan, G., Horvath, T.L., Gao, X.-B.,
and Diano, S. (2010). Corticosterone regulates synaptic input organization of
POMC and NPY/AgRP neurons in adult mice. Endocrinology 151, 5395–5402.
Hagan, M.M., Wauford, P.K., Chandler, P.C., Jarrett, L.A., Rybak, R.J., and
Blackburn, K. (2002). A new animal model of binge eating: key synergistic
role of past caloric restriction and stress. Physiol. Behav. 77, 45–54.
Hall, J.E., da Silva, A.A., do Carmo, J.M., Dubinion, J., Hamza, S., Munusamy,
S., Smith, G., and Stec, D.E. (2010). Obesity-induced hypertension: role of
sympathetic nervous system, leptin, and melanocortins. J. Biol. Chem. 285,
17271–17276.
Halter, J.B., Beard, J.C., and Porte, D., Jr. (1984). Islet function and stress
hyperglycemia: plasma glucose and epinephrine interaction. Am. J. Physiol.
247, E47–E52.
Haskell-Luevano, C., and Monck, E.K. (2001). Agouti-related protein functions
as an inverse agonist at a constitutively active brain melanocortin-4 receptor.
Regul. Pept. 99, 1–7.Haskell-Luevano, C., Hendrata, S., North, C., Sawyer, T.K., Hadley, M.E.,
Hruby, V.J., Dickinson, C., and Gantz, I. (1997). Discovery of prototype pepti-
domimetic agonists at the human melanocortin receptors MC1R and MC4R.
J. Med. Chem. 40, 2133–2139.
Heiman, M.L., Ahima, R.S., Craft, L.S., Schoner, B., Stephens, T.W., and Flier,
J.S. (1997). Leptin inhibition of the hypothalamic-pituitary-adrenal axis in
response to stress. Endocrinology 138, 3859–3863.
Heisler, L.K., Pronchuk, N., Nonogaki, K., Zhou, L., Raber, J., Tung, L., Yeo,
G.S.H., O’Rahilly, S., Colmers, W.F., Elmquist, J.K., and Tecott, L.H. (2007).
Serotonin activates the hypothalamic-pituitary-adrenal axis via serotonin 2C
receptor stimulation. J. Neurosci. 27, 6956–6964.
Herman, J.P., Adams, D., and Prewitt, C. (1995). Regulatory changes in neuro-
endocrine stress-integrative circuitry produced by a variable stress paradigm.
Neuroendocrinology 61, 180–190.
Hill, M.N., and McEwen, B.S. (2010). Involvement of the endocannabinoid
system in the neurobehavioural effects of stress and glucocorticoids. Prog.
Neuropsychopharmacol. Biol. Psychiatry 34, 791–797.
Hill, M.N., Patel, S., Carrier, E.J., Rademacher, D.J., Ormerod, B.K., Hillard,
C.J., and Gorzalka, B.B. (2005). Downregulation of endocannabinoid signaling
in the hippocampus following chronic unpredictable stress. Neuropsycho-
pharmacology 30, 508–515.
Hoffstedt, J., Arner, P., Hellers, G., and Lo¨nnqvist, F. (1997). Variation in
adrenergic regulation of lipolysis between omental and subcutaneous adipo-
cytes from obese and non-obese men. J. Lipid Res. 38, 795–804.
Hollister, L.E., Johnson, K., Boukhabza, D., andGillespie, H.K. (1981). Aversive
effects of naltrexone in subjects not dependent on opiates. Drug Alcohol
Depend. 8, 37–41.
Holst, J.J. (2007). The physiology of glucagon-like peptide 1. Physiol. Rev. 87,
1409–1439.
Hommel, J.D., Trinko, R., Sears, R.M., Georgescu, D., Liu, Z.W., Gao, X.B.,
Thurmon, J.J., Marinelli, M., and DiLeone, R.J. (2006). Leptin receptor
signaling in midbrain dopamine neurons regulates feeding. Neuron 51,
801–810.
Hryhorczuk, C., Sharma, S., and Fulton, S.E. (2013). Metabolic disturbances
connecting obesity and depression. Front. Neurosci. 7, 177.
Huda, M.S.B., Mani, H., Dovey, T., Halford, J.C.G., Boyland, E., Daousi, C.,
Wilding, J.P.H., and Pinkney, J. (2010). Ghrelin inhibits autonomic function in
healthy controls, but has no effect on obese and vagotomized subjects. Clin.
Endocrinol. (Oxf.) 73, 678–685.
Kamilaris, T.C., Johnson, E.O., Calogero, A.E., Kalogeras, K.T., Bernardini, R.,
Chrousos, G.P., and Gold, P.W. (1992). Cholecystokinin-octapeptide stimu-
lates hypothalamic-pituitary-adrenal function in rats: role of corticotropin-
releasing hormone. Endocrinology 130, 1764–1774.
Kanehisa, M., Akiyoshi, J., Kitaichi, T., Matsushita, H., Tanaka, E., Kodama, K.,
Hanada, H., and Isogawa, K. (2006). Administration of antisense DNA for
ghrelin causes an antidepressant and anxiolytic response in rats. Prog. Neuro-
psychopharmacol. Biol. Psychiatry 30, 1403–1407.
Karlsson, J., Taft, C., Sjo¨stro¨m, L., Torgerson, J.S., and Sullivan, M. (2003).
Psychosocial functioning in the obese before and after weight reduction:
construct validity and responsiveness of the Obesity-related Problems scale.
Int. J. Obes. Relat. Metab. Disord. 27, 617–630.
Kelley, A.E., and Berridge, K.C. (2002). The neuroscience of natural rewards:
relevance to addictive drugs. J. Neurosci. 22, 3306–3311.
Kim, Y., Yang, H.Y., Kim, A.-J., and Lim, Y. (2013). Academic stress levels
were positively associated with sweet food consumption among Korean
high-school students. Nutrition 29, 213–218.
Kinzig, K.P., D’Alessio, D.A., Herman, J.P., Sakai, R.R., Vahl, T.P., Figueiredo,
H.F., Murphy, E.K., and Seeley, R.J. (2003). CNS glucagon-like peptide-1
receptors mediate endocrine and anxiety responses to interoceptive and
psychogenic stressors. J. Neurosci. 23, 6163–6170.
Kivima¨ki, M., Hamer, M., Batty, G.D., Geddes, J.R., Tabak, A.G., Pentti, J.,
Virtanen, M., and Vahtera, J. (2010). Antidepressant medication use, weight
gain, and risk of type 2 diabetes: a population-based study. Diabetes Care
33, 2611–2616.Cell Metabolism 19, June 3, 2014 ª2014 Elsevier Inc. 921
Cell Metabolism
PerspectiveKojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H., and Kangawa, K.
(1999). Ghrelin is a growth-hormone-releasing acylated peptide from stomach.
Nature 402, 656–660.
Kopelman, P., Groot, G. de H., Rissanen, A., Rossner, S., Toubro, S., Palmer,
R., Hallam, R., Bryson, A., and Hickling, R.I. (2010). Weight loss, HbA1c reduc-
tion, and tolerability of cetilistat in a randomized, placebo-controlled phase 2
trial in obese diabetics: comparison with orlistat (Xenical). Obesity (Silver
Spring) 18, 108–115.
Kraly, F.S., Carty, W.J., Resnick, S., and Smith, G.P. (1978). Effect of cholecys-
tokinin on meal size and intermeal interval in the sham-feeding rat. J. Comp.
Physiol. Psychol. 92, 697–707.
Kreymann, B., Williams, G., Ghatei, M.A., and Bloom, S.R. (1987). Glucagon-
like peptide-1 7-36: a physiological incretin in man. Lancet 2, 1300–1304.
Kunos, G., and Tam, J. (2011). The case for peripheral CB1 receptor blockade
in the treatment of visceral obesity and its cardiometabolic complications. Br.
J. Pharmacol. 163, 1423–1431.
la Fleur, S.E., Houshyar, H., Roy, M., and Dallman, M.F. (2005). Choice of lard,
but not total lard calories, damps adrenocorticotropin responses to restraint.
Endocrinology 146, 2193–2199.
Larsen, P.J., Tang-Christensen, M., and Jessop, D.S. (1997). Central adminis-
tration of glucagon-like peptide-1 activates hypothalamic neuroendocrine
neurons in the rat. Endocrinology 138, 4445–4455.
Laugero, K.D., Bell, M.E., Bhatnagar, S., Soriano, L., and Dallman, M.F. (2001).
Sucrose ingestion normalizes central expression of corticotropin-releasing-
factor messenger ribonucleic acid and energy balance in adrenalectomized
rats: a glucocorticoid-metabolic-brain axis? Endocrinology 142, 2796–2804.
Laugero, K.D., Falcon, L.M., and Tucker, K.L. (2011). Relationship between
perceived stress and dietary and activity patterns in older adults participating
in the Boston Puerto Rican Health Study. Appetite 56, 194–204.
Lemmens, S.G., Rutters, F., Born, J.M., and Westerterp-Plantenga, M.S.
(2011). Stress augments food ‘wanting’ and energy intake in visceral over-
weight subjects in the absence of hunger. Physiol. Behav. 103, 157–163.
Levin, B.E., Richard, D., Michel, C., and Servatius, R. (2000). Differential stress
responsivity in diet-induced obese and resistant rats. Am. J. Physiol. Regul.
Integr. Comp. Physiol. 279, R1357–R1364.
Lin, Y., Matsumura, K., Fukuhara, M., Kagiyama, S., Fujii, K., and Iida, M.
(2004). Ghrelin acts at the nucleus of the solitary tract to decrease arterial
pressure in rats. Hypertension 43, 977–982.
Liu, J., Garza, J.C., Li, W., and Lu, X.-Y. (2013). Melanocortin-4 receptor in the
medial amygdala regulates emotional stress-induced anxiety-like behaviour,
anorexia and corticosterone secretion. Int. J. Neuropsychopharmacol. 16,
105–120.
Lo¨nn, L., Kvist, H., Ernest, I., and Sjo¨stro¨m, L. (1994). Changes in body compo-
sition and adipose tissue distribution after treatment of women with Cushing’s
syndrome. Metabolism 43, 1517–1522.
Lu, X.-Y., Barsh, G.S., Akil, H., and Watson, S.J. (2003). Interaction between
alpha-melanocyte-stimulating hormone and corticotropin-releasing hormone
in the regulation of feeding and hypothalamo-pituitary-adrenal responses.
J. Neurosci. 23, 7863–7872.
Luppino, F.S., de Wit, L.M., Bouvy, P.F., Stijnen, T., Cuijpers, P., Penninx,
B.W.J.H., and Zitman, F.G. (2010). Overweight, obesity, and depression: a
systematic review and meta-analysis of longitudinal studies. Arch. Gen. Psy-
chiatry 67, 220–229.
Lutter, M., Sakata, I., Osborne-Lawrence, S., Rovinsky, S.A., Anderson, J.G.,
Jung, S., Birnbaum, S., Yanagisawa, M., Elmquist, J.K., Nestler, E.J., and Zig-
man, J.M. (2008). The orexigenic hormone ghrelin defends against depressive
symptoms of chronic stress. Nat. Neurosci. 11, 752–753.
Macht, M., and Mueller, J. (2007). Immediate effects of chocolate on experi-
mentally induced mood states. Appetite 49, 667–674.
Magarin˜os, A.M., and McEwen, B.S. (1995). Stress-induced atrophy of apical
dendrites of hippocampal CA3c neurons: involvement of glucocorticoid
secretion and excitatory amino acid receptors. Neuroscience 69, 89–98.
Makino, S., Smith, M.A., and Gold, P.W. (1995). Increased expression of
corticotropin-releasing hormone and vasopressin messenger ribonucleic922 Cell Metabolism 19, June 3, 2014 ª2014 Elsevier Inc.acid (mRNA) in the hypothalamic paraventricular nucleus during repeated
stress: association with reduction in glucocorticoid receptor mRNA levels.
Endocrinology 136, 3299–3309.
Maniscalco, J.W., and Rinaman, L. (2013). Overnight food deprivation mark-
edly attenuates hindbrain noradrenergic, glucagon-like peptide-1, and hypo-
thalamic neural responses to exogenous cholecystokinin in male rats. Physiol.
Behav. 121, 35–42.
Mark, A.L., Shaffer, R.A., Correia, M.L., Morgan, D.A., Sigmund, C.D., and
Haynes, W.G. (1999). Contrasting blood pressure effects of obesity in leptin-
deficient ob/ob mice and agouti yellow obese mice. J. Hypertens. 17, 1949–
1953.
Markus, R., Panhuysen, G., Tuiten, A., and Koppeschaar, H. (2000). Effects
of food on cortisol and mood in vulnerable subjects under controllable
and uncontrollable stress. Physiol. Behav. 70, 333–342.
Matsumura, K., Tsuchihashi, T., Fujii, K., Abe, I., and Iida, M. (2002). Central
ghrelin modulates sympathetic activity in conscious rabbits. Hypertension
40, 694–699.
Mazure, C.M. (1998). Life stressors as risk factors in depression. Clin. Psychol.
Sci. Pract. 5, 291–313.
McCann, B.S., Warnick, G.R., and Knopp, R.H. (1990). Changes in plasma
lipids and dietary intake accompanying shifts in perceived workload and
stress. Psychosom. Med. 52, 97–108.
Mendelson, J.H., Ellingboe, J., Keuhnle, J.C., and Mello, N.K. (1978). Effects
of naltrexone on mood and neuroendocrine function in normal adult males.
Psychoneuroendocrinology 3, 231–236.
Michopoulos, V., Toufexis, D., and Wilson, M.E. (2012). Social stress interacts
with diet history to promote emotional feeding in females. Psychoneuroendoc-
rinology 37, 1479–1490.
Moran, T.H. (2006). Gut peptide signaling in the controls of food intake. Obesity
(Silver Spring) 14 (Suppl 5 ), 250S–253S.
Morton, G.J., Blevins, J.E., Williams, D.L., Niswender, K.D., Gelling, R.W.,
Rhodes, C.J., Baskin, D.G., and Schwartz, M.W. (2005). Leptin action in the
forebrain regulates the hindbrain response to satiety signals. J. Clin. Invest.
115, 703–710.
Muntzel, M.S., Morgan, D.A., Mark, A.L., and Johnson, A.K. (1994). Intracere-
broventricular insulin produces nonuniform regional increases in sympathetic
nerve activity. Am. J. Physiol. 267, R1350–R1355.
Nakabayashi, H., Nishizawa, M., Nakagawa, A., Takeda, R., and Niijima, A.
(1996). Vagal hepatopancreatic reflex effect evoked by intraportal appearance
of tGLP-1. Am. J. Physiol. 271, E808–E813.
Nathan, P.J., O’Neill, B.V., Napolitano, A., and Bullmore, E.T. (2011).
Neuropsychiatric adverse effects of centrally acting antiobesity drugs. CNS
Neurosci. Ther. 17, 490–505.
Need, A.B., Davis, R.J., Alexander-Chacko, J.T., Eastwood, B., Chernet, E.,
Phebus, L.A., Sindelar, D.K., and Nomikos, G.G. (2006). The relationship of
in vivo central CB1 receptor occupancy to changes in cortical monoamine
release and feeding elicited by CB1 receptor antagonists in rats. Psychophar-
macology (Berl.) 184, 26–35.
Nijenhuis, W.A., Oosterom, J., and Adan, R.A. (2001). AgRP(83-132) acts as an
inverse agonist on the human-melanocortin-4 receptor. Mol. Endocrinol. 15,
164–171.
Nogueiras, R., Veyrat-Durebex, C., Suchanek, P.M., Klein, M., Tscho¨p, J.,
Caldwell, C., Woods, S.C., Wittmann, G., Watanabe, M., Liposits, Z., et al.
(2008). Peripheral, but not central, CB1 antagonism provides food intake-
independent metabolic benefits in diet-induced obese rats. Diabetes 57,
2977–2991.
Norgren, R. (1978). Projections from the nucleus of the solitary tract in the rat.
Neuroscience 3, 207–218.
O’Malley, S.S., Krishnan-Sarin, S., Farren, C., Sinha, R., and Kreek, M.J.
(2002). Naltrexone decreases craving and alcohol self-administration in
alcohol-dependent subjects and activates the hypothalamo-pituitary-adreno-
cortical axis. Psychopharmacology (Berl.) 160, 19–29.
Oliver, G., and Wardle, J. (1999). Perceived effects of stress on food choice.
Physiol. Behav. 66, 511–515.
Cell Metabolism
PerspectiveOstman, J., Arner, P., Engfeldt, P., and Kager, L. (1979). Regional differences in
the control of lipolysis in human adipose tissue. Metabolism 28, 1198–1205.
Pacak, K., McCarty, R., Palkovits, M., Cizza, G., Kopin, I.J., Goldstein, D.S.,
and Chrousos, G.P. (1995). Decreased central and peripheral catecholamin-
ergic activation in obese Zucker rats. Endocrinology 136, 4360–4367.
Pan, A., Sun, Q., Czernichow, S., Kivimaki, M., Okereke, O.I., Lucas, M., Man-
son, J.E., Ascherio, A., and Hu, F.B. (2012). Bidirectional association between
depression and obesity in middle-aged and older women. Int. J. Obes. (Lond.)
36, 595–602.
Pankevich, D.E., Teegarden, S.L., Hedin, A.D., Jensen, C.L., and Bale, T.L.
(2010). Caloric restriction experience reprograms stress and orexigenic path-
ways and promotes binge eating. J. Neurosci. 30, 16399–16407.
Papageorgiou, G.M., Papakonstantinou, A., Mamplekou, E., Terzis, I., and
Melissas, J. (2002). Pre- and postoperative psychological characteristics in
morbidly obese patients. Obes. Surg. 12, 534–539.
Patel, S., and Hillard, C.J. (2008). Adaptations in endocannabinoid signaling
in response to repeated homotypic stress: a novel mechanism for stress
habituation. Eur. J. Neurosci. 27, 2821–2829.
Paykel, E.S., Myers, J.K., Dienelt, M.N., Klerman, G.L., Lindenthal, J.J., and
Pepper, M.P. (1969). Life events and depression. A controlled study. Arch.
Gen. Psychiatry 21, 753–760.
Pecoraro, N., Reyes, F., Gomez, F., Bhargava, A., and Dallman, M.F. (2004).
Chronic stress promotes palatable feeding, which reduces signs of stress:
feedforward and feedback effects of chronic stress. Endocrinology 145,
3754–3762.
Perello´, M., and Zigman, J.M. (2012). The role of ghrelin in reward-based
eating. Biol. Psychiatry 72, 347–353.
Perello, M., Sakata, I., Birnbaum, S., Chuang, J.-C., Osborne-Lawrence, S.,
Rovinsky, S.A., Woloszyn, J., Yanagisawa, M., Lutter, M., and Zigman, J.M.
(2010). Ghrelin increases the rewarding value of high-fat diet in an orexin-
dependent manner. Biol. Psychiatry 67, 880–886.
Peterha¨nsel, C., Petroff, D., Klinitzke, G., Kersting, A., and Wagner, B. (2013).
Risk of completed suicide after bariatric surgery: a systematic review. Obes.
Rev. 14, 369–382.
Pollard, T.M., Steptoe, A., Canaan, L., Davies, G.J., and Wardle, J. (1995).
Effects of academic examination stress on eating behavior and blood lipid
levels. Int. J. Behav. Med. 2, 299–320.
Popper, R., Smits, G., Meiselman, H.L., and Hirsch, E. (1989). Eating in
combat: a survey of U.S. Marines. Mil. Med. 154, 619–623.
Quarta, C., Bellocchio, L., Mancini, G., Mazza, R., Cervino, C., Braulke, L.J.,
Fekete, C., Latorre, R., Nanni, C., Bucci, M., et al. (2010). CB(1) signaling in
forebrain and sympathetic neurons is a key determinant of endocannabinoid
actions on energy balance. Cell Metab. 11, 273–285.
Radley, J.J., Rocher, A.B., Rodriguez, A., Ehlenberger, D.B., Dammann, M.,
McEwen, B.S., Morrison, J.H., Wearne, S.L., and Hof, P.R. (2008). Repeated
stress alters dendritic spine morphology in the rat medial prefrontal cortex.
J. Comp. Neurol. 507, 1141–1150.
Raeder, M.B., Bjelland, I., Emil Vollset, S., and Steen, V.M. (2006). Obesity,
dyslipidemia, and diabetes with selective serotonin reuptake inhibitors: the
Hordaland Health Study. J. Clin. Psychiatry 67, 1974–1982.
Rahmouni, K. (2010). Obesity, sympathetic overdrive, and hypertension: the
leptin connection. Hypertension 55, 844–845.
Rahmouni, K., Haynes, W.G., Morgan, D.A., and Mark, A.L. (2003). Role of
melanocortin-4 receptors in mediating renal sympathoactivation to leptin
and insulin. J. Neurosci. 23, 5998–6004.
Raybould, H.E. (1991). Capsaicin-sensitive vagal afferents and CCK in inhi-
bition of gastric motor function induced by intestinal nutrients. Peptides 12,
1279–1283.
Reich, C.G., Taylor, M.E., and McCarthy, M.M. (2009). Differential effects
of chronic unpredictable stress on hippocampal CB1 receptors in male and
female rats. Behav. Brain Res. 203, 264–269.
Ren, J. (2004). Leptin and hyperleptinemia - from friend to foe for cardiovascu-
lar function. J. Endocrinol. 181, 1–10.Riedy, C.A., Chavez, M., Figlewicz, D.P., and Woods, S.C. (1995).
Central insulin enhances sensitivity to cholecystokinin. Physiol. Behav. 58,
755–760.
Rouach, V., Bloch, M., Rosenberg, N., Gilad, S., Limor, R., Stern, N., and
Greenman, Y. (2007). The acute ghrelin response to a psychological stress
challenge does not predict the post-stress urge to eat. Psychoneuroendo-
crinology 32, 693–702.
Rowe, J.W., Young, J.B., Minaker, K.L., Stevens, A.L., Pallotta, J., and Lands-
berg, L. (1981). Effect of insulin and glucose infusions on sympathetic nervous
system activity in normal man. Diabetes 30, 219–225.
Rudenga, K.J., Sinha, R., and Small, D.M. (2013). Acute stress potentiates
brain response to milkshake as a function of body weight and chronic stress.
Int. J. Obes. (Lond.) 37, 309–316.
Rutters, F., Nieuwenhuizen, A.G., Lemmens, S.G.T., Born, J.M., and Wester-
terp-Plantenga, M.S. (2009). Acute stress-related changes in eating in the
absence of hunger. Obesity (Silver Spring) 17, 72–77.
Ryan, K.K., Woods, S.C., and Seeley, R.J. (2012). Central nervous system
mechanisms linking the consumption of palatable high-fat diets to the defense
of greater adiposity. Cell Metab. 15, 137–149.
Ryan, K.K., Mul, J.D., Clemmensen, C., Egan, A.E., Begg, D.P., Halcomb, K.,
Seeley, R.J., Herman, J.P., and Ulrich-Lai, Y.M. (2014). Loss of melanocortin-
4 receptor function attenuates HPA responses to psychological stress. Psy-
choneuroendocrinology. http://dx.doi.org/10.1016/j.psyneuen.2014.01.010.
Sampson, D., Muscat, R., Phillips, G., and Willner, P. (1992). Decreased
reactivity to sweetness following chronic exposure to mild unpredictable
stress or acute administration of pimozide. Neurosci. Biobehav. Rev. 16,
519–524.
Saper, C.B., Chou, T.C., and Elmquist, J.K. (2002). The need to feed: homeo-
static and hedonic control of eating. Neuron 36, 199–211.
Sarkar, S., Fekete, C., Le´gra´di, G., and Lechan, R.M. (2003). Glucagon like
peptide-1 (7-36) amide (GLP-1) nerve terminals densely innervate cortico-
tropin-releasing hormone neurons in the hypothalamic paraventricular nu-
cleus. Brain Res. 985, 163–168.
Schellekens, H., Finger, B.C., Dinan, T.G., and Cryan, J.F. (2012). Ghrelin
signalling and obesity: at the interface of stress, mood and food reward.
Pharmacol. Ther. 135, 316–326.
Schwartz, M.W., Woods, S.C., Porte, D., Jr., Seeley, R.J., and Baskin, D.G.
(2000). Central nervous system control of food intake. Nature 404, 661–671.
Sclafani, A., and Ackroff, K. (2012). Role of gut nutrient sensing in stimulating
appetite and conditioning food preferences. Am. J. Physiol. Regul. Integr.
Comp. Physiol. 302, R1119–R1133.
Seeley, R.J., Yagaloff, K.A., Fisher, S.L., Burn, P., Thiele, T.E., van Dijk, G.,
Baskin, D.G., and Schwartz, M.W. (1997). Melanocortin receptors in leptin
effects. Nature 390, 349.
Shide, D.J., and Blass, E.M. (1989). Opioidlike effects of intraoral infusions of
corn oil and polycose on stress reactions in 10-day-old rats. Behav. Neurosci.
103, 1168–1175.
Shimizu, S., Akiyama, T., Kawada, T., Sonobe, T., Kamiya, A., Shishido, T., To-
kudome, T., Hosoda, H., Shirai, M., Kangawa, K., and Sugimachi, M. (2011).
Centrally administered ghrelin activates cardiac vagal nerve in anesthetized
rabbits. Auton. Neurosci. 162, 60–65.
Silvestri, C., and Di Marzo, V. (2013). The endocannabinoid system in energy
homeostasis and the etiopathology of metabolic disorders. Cell Metab. 17,
475–490.
Smith, S.R., Weissman, N.J., Anderson, C.M., Sanchez, M., Chuang, E.,
Stubbe, S., Bays, H., and Shanahan, W.R.; Behavioral Modification and
Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group
(2010). Multicenter, placebo-controlled trial of lorcaserin for weight manage-
ment. N. Engl. J. Med. 363, 245–256.
Sohn, J.-W., Harris, L.E., Berglund, E.D., Liu, T., Vong, L., Lowell, B.B., Balth-
asar, N., Williams, K.W., and Elmquist, J.K. (2013). Melanocortin 4 receptors
reciprocally regulate sympathetic and parasympathetic preganglionic neu-
rons. Cell 152, 612–619.Cell Metabolism 19, June 3, 2014 ª2014 Elsevier Inc. 923
Cell Metabolism
PerspectiveSpencer, S.J., Xu, L., Clarke, M.A., Lemus, M., Reichenbach, A., Geenen, B.,
Kozicz, T., and Andrews, Z.B. (2012). Ghrelin regulates the hypothalamic-pitu-
itary-adrenal axis and restricts anxiety after acute stress. Biol. Psychiatry 72,
457–465.
Stefater, M.A., Wilson-Pe´rez, H.E., Chambers, A.P., Sandoval, D.A., and
Seeley, R.J. (2012). All bariatric surgeries are not created equal: insights
from mechanistic comparisons. Endocr. Rev. 33, 595–622.
Stengel, A., Wang, L., and Tache´, Y. (2011). Stress-related alterations of acyl
and desacyl ghrelin circulating levels: mechanisms and functional implica-
tions. Peptides 32, 2208–2217.
Strack, A.M., Akana, S.F., Horsley, C.J., and Dallman, M.F. (1997). A hyper-
caloric load induces thermogenesis but inhibits stress responses in the SNS
and HPA system. Am. J. Physiol. 272, R840–R848.
Stunkard, A.J. (1957). The dieting depression; incidence and clinical charac-
teristics of untoward responses to weight reduction regimens. Am. J. Med.
23, 77–86.
Stunkard, A.J., and Wadden, T.A. (1992). Psychological aspects of severe
obesity. Am. J. Clin. Nutr. Suppl. 55, 524S–532S.
Stunkard, A.J., Faith, M.S., and Allison, K.C. (2003). Depression and obesity.
Biol. Psychiatry 54, 330–337.
Tallam, L.S., da Silva, A.A., and Hall, J.E. (2006). Melanocortin-4 receptor
mediates chronic cardiovascular andmetabolic actions of leptin. Hypertension
48, 58–64.
Tam, J., Cinar, R., Liu, J., Godlewski, G., Wesley, D., Jourdan, T., Szanda, G.,
Mukhopadhyay, B., Chedester, L., Liow, J.-S., et al. (2012). Peripheral canna-
binoid-1 receptor inverse agonism reduces obesity by reversing leptin resis-
tance. Cell Metab. 16, 167–179.
Tataranni, P.A., Larson, D.E., Snitker, S., Young, J.B., Flatt, J.P., and Ravussin,
E. (1996). Effects of glucocorticoids on energy metabolism and food intake in
humans. Am. J. Physiol. 271, E317–E325.
Tauchi, M., Zhang, R., D’Alessio, D.A., Seeley, R.J., and Herman, J.P. (2008).
Role of central glucagon-like peptide-1 in hypothalamo-pituitary-adrenocor-
tical facilitation following chronic stress. Exp. Neurol. 210, 458–466.
Tempel, D.L., McEwen, B.S., and Leibowitz, S.F. (1992). Effects of adrenal
steroid agonists on food intake and macronutrient selection. Physiol. Behav.
52, 1161–1166.
Thomas, C., Pellicciari, R., Pruzanski, M., Auwerx, J., and Schoonjans, K.
(2008). Targeting bile-acid signalling for metabolic diseases. Nat. Rev. Drug
Discov. 7, 678–693.
Tomiyama, A.J., Dallman,M.F., and Epel, E.S. (2011). Comfort food is comfort-
ing to thosemost stressed: evidence of the chronic stress response network in
high stress women. Psychoneuroendocrinology 36, 1513–1519.
Tomiyama, A.J., Schamarek, I., Lustig, R.H., Kirschbaum, C., Puterman, E.,
Havel, P.J., and Epel, E.S. (2012). Leptin concentrations in response to acute
stress predict subsequent intake of comfort foods. Physiol. Behav. 107, 34–39.
Torgerson, J.S., Hauptman, J., Boldrin, M.N., and Sjo¨stro¨m, L. (2004). XENical
in the prevention of diabetes in obese subjects (XENDOS) study: a randomized
study of orlistat as an adjunct to lifestyle changes for the prevention of type 2
diabetes in obese patients. Diabetes Care 27, 155–161.
Tryon, M.S., Carter, C.S., Decant, R., and Laugero, K.D. (2013a). Chronic
stress exposure may affect the brain’s response to high calorie food cues
and predispose to obesogenic eating habits. Physiol. Behav. 120, 233–242.
Tryon, M.S., DeCant, R., and Laugero, K.D. (2013b). Having your cake and
eating it too: a habit of comfort food may link chronic social stress exposure
and acute stress-induced cortisol hyporesponsiveness. Physiol. Behav. 114-
115, 32–37.
Tscho¨p, M., Smiley, D.L., and Heiman, M.L. (2000). Ghrelin induces adiposity
in rodents. Nature 407, 908–913.
Turton, M.D., O’Shea, D., Gunn, I., Beak, S.A., Edwards, C.M., Meeran, K.,
Choi, S.J., Taylor, G.M., Heath, M.M., Lambert, P.D., et al. (1996). A role for
glucagon-like peptide-1 in the central regulation of feeding. Nature 379, 69–72.
Ulrich-Lai, Y.M., and Herman, J.P. (2009). Neural regulation of endocrine and
autonomic stress responses. Nat. Rev. Neurosci. 10, 397–409.924 Cell Metabolism 19, June 3, 2014 ª2014 Elsevier Inc.Ulrich-Lai, Y.M., Ostrander, M.M., Thomas, I.M., Packard, B.A., Furay, A.R.,
Dolgas, C.M., Van Hooren, D.C., Figueiredo, H.F., Mueller, N.K., Choi, D.C.,
and Herman, J.P. (2007). Daily limited access to sweetened drink attenuates
hypothalamic-pituitary-adrenocortical axis stress responses. Endocrinology
148, 1823–1834.
Ulrich-Lai, Y.M., Christiansen, A.M., Ostrander, M.M., Jones, A.A., Jones,
K.R., Choi, D.C., Krause, E.G., Evanson, N.K., Furay, A.R., Davis, J.F., et al.
(2010). Pleasurable behaviors reduce stress via brain reward pathways.
Proc. Natl. Acad. Sci. USA 107, 20529–20534.
Vahl, T.P., Tauchi, M., Durler, T.S., Elfers, E.E., Fernandes, T.M., Bitner, R.D.,
Ellis, K.S., Woods, S.C., Seeley, R.J., Herman, J.P., and D’Alessio, D.A. (2007).
Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in
the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance
in rats. Endocrinology 148, 4965–4973.
van den Top, M., Lee, K., Whyment, A.D., Blanks, A.M., and Spanswick, D.
(2004). Orexigen-sensitive NPY/AgRP pacemaker neurons in the hypothalam-
ic arcuate nucleus. Nat. Neurosci. 7, 493–494.
van Dijk, G., Donahey, J.C.K., Thiele, T.E., Scheurink, A.J., Steffens, A.B., Wil-
kinson, C.W., Tenenbaum, R., Campfield, L.A., Burn, P., Seeley, R.J., and
Woods, S.C. (1997). Central leptin stimulates corticosterone secretion at the
onset of the dark phase. Diabetes 46, 1911–1914.
Van Gaal, L.F., Rissanen, A.M., Scheen, A.J., Ziegler, O., and Ro¨ssner, S.;
RIO-Europe StudyGroup (2005). Effects of the cannabinoid-1 receptor blocker
rimonabant on weight reduction and cardiovascular risk factors in overweight
patients: 1-year experience from the RIO-Europe study. Lancet 365, 1389–
1397.
Viana, A., Rates, S., Naudin, B., Janin, F., Costentin, J., and do Rego, J.-C.
(2008). Effects of acute or 3-day treatments of Hypericum caprifoliatum
Cham. & Schltdt. (Guttiferae) extract or of two established antidepressants
on basal and stress-induced increase in serum and brain corticosterone levels.
J. Psychopharmacol. (Oxford) 22, 681–690.
Vyas, A., Mitra, R., Shankaranarayana Rao, B.S., and Chattarji, S. (2002).
Chronic stress induces contrasting patterns of dendritic remodeling in hippo-
campal and amygdaloid neurons. J. Neurosci. 22, 6810–6818.
Wardle, J., Steptoe, A., Oliver, G., and Lipsey, Z. (2000). Stress, dietary re-
straint and food intake. J. Psychosom. Res. 48, 195–202.
Weinstein, S.E., Shide, D.J., and Rolls, B.J. (1997). Changes in food intake in
response to stress in men and women: psychological factors. Appetite 28,
7–18.
Weintraub, M., Hasday, J.D., Mushlin, A.I., and Lockwood, D.H. (1984). A dou-
ble-blind clinical trial in weight control. Use of fenfluramine and phentermine
alone and in combination. Arch. Intern. Med. 144, 1143–1148.
Wilding, J., Van Gaal, L., Rissanen, A., Vercruysse, F., and Fitchet, M.; OBES-
002 Study Group (2004). A randomized double-blind placebo-controlled study
of the long-term efficacy and safety of topiramate in the treatment of obese
subjects. Int. J. Obes. Relat. Metab. Disord. 28, 1399–1410.
Williams, K.W., and Elmquist, J.K. (2012). From neuroanatomy to behavior:
central integration of peripheral signals regulating feeding behavior. Nat. Neu-
rosci. 15, 1350–1355.
Williams, D.L., Baskin, D.G., and Schwartz, M.W. (2006). Leptin regulation
of the anorexic response to glucagon-like peptide-1 receptor stimulation. Dia-
betes 55, 3387–3393.
Willner, P., and Healy, S. (1994). Decreased hedonic responsiveness during a
brief depressive mood swing. J. Affect. Disord. 32, 13–20.
Willner, P., Moreau, J.L., Nielsen, C.K., Papp, M., and Sluzewska, A. (1996).
Decreased hedonic responsiveness following chronic mild stress is not sec-
ondary to loss of body weight. Physiol. Behav. 60, 129–134.
Willner, P., Benton, D., Brown, E., Cheeta, S., Davies, G., Morgan, J., and
Morgan, M. (1998). ‘‘Depression’’ increases ‘‘craving’’ for sweet rewards in
animal and human models of depression and craving. Psychopharmacology
(Berl.) 136, 272–283.
Wilson, M.E., Fisher, J., and Brown, J. (2005). Chronic subcutaneous leptin
infusion diminishes the responsiveness of the hypothalamic-pituitary-adrenal
(HPA) axis in female rhesus monkeys. Physiol. Behav. 84, 449–458.
Cell Metabolism
PerspectiveWoods, S.C., and D’Alessio, D.A. (2008). Central control of body weight and
appetite. J. Clin. Endocrinol. Metab. 93 (Suppl 1 ), S37–S50.
Wren, A.M., and Bloom, S.R. (2007). Gut hormones and appetite control.
Gastroenterology 132, 2116–2130.
Xu, C., He, J., Jiang, H., Zu, L., Zhai, W., Pu, S., and Xu, G. (2009). Direct effect
of glucocorticoids on lipolysis in adipocytes. Mol. Endocrinol. 23, 1161–1170.
Yamaguchi, N. (1992). Sympathoadrenal system in neuroendocrine control of
glucose: mechanisms involved in the liver, pancreas, and adrenal gland under
hemorrhagic and hypoglycemic stress. Can. J. Physiol. Pharmacol. 70,
167–206.
Yamamoto, H., Lee, C.E., Marcus, J.N., Williams, T.D., Overton, J.M., Lopez,
M.E., Hollenberg, A.N., Baggio, L., Saper, C.B., Drucker, D.J., and Elmquist,
J.K. (2002). Glucagon-like peptide-1 receptor stimulation increases blood
pressure and heart rate and activates autonomic regulatory neurons. J. Clin.
Invest. 110, 43–52.
Yamamoto, H., Kishi, T., Lee, C.E., Choi, B.J., Fang, H., Hollenberg, A.N.,
Drucker, D.J., and Elmquist, J.K. (2003). Glucagon-like peptide-1-responsive
catecholamine neurons in the area postrema link peripheral glucagon-like
peptide-1 with central autonomic control sites. J. Neurosci. 23, 2939–2946.York, D.A., Singer, L., Thomas, S., and Bray, G.A. (2000). Effect of topiramate
on body weight and body composition of osborne-mendel rats fed a high-fat
diet: alterations in hormones, neuropeptide, and uncoupling-protein mRNAs.
Nutrition 16, 967–975.
Yu, W.Z., Silva, R.M., Sclafani, A., Delamater, A.R., and Bodnar, R.J. (2000).
Pharmacology of flavor preference conditioning in sham-feeding rats: effects
of dopamine receptor antagonists. Pharmacol. Biochem. Behav. 65, 635–647.
Zakrzewska, K.E., Cusin, I., Stricker-Krongrad, A., Boss, O., Ricquier, D.,
Jeanrenaud, B., and Rohner-Jeanrenaud, F. (1999). Induction of obesity and
hyperleptinemia by central glucocorticoid infusion in the rat. Diabetes 48,
365–370.
Zheng, H., Liu, X., Li, Y., Mishra, P.K., and Patel, K.P. (2013). Attenuated
Dopaminergic Tone in the Paraventricular Nucleus Contributing to Sympa-
tho-Excitation in Rats with Type 2 Diabetes. Am. J. Physiol. Regul. Integr.
Comp. Physiol. 306, http://dx.doi.org/10.1152/ajpregu.00323.2013.
Zwanzger, P., Domschke, K., and Bradwejn, J. (2012). Neuronal network of
panic disorder: the role of the neuropeptide cholecystokinin. Depress. Anxiety
29, 762–774.Cell Metabolism 19, June 3, 2014 ª2014 Elsevier Inc. 925
